var title_f20_32_20992="Algorithm for the evaluation of flushing";
var content_f20_32_20992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Evaluation of flushing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 699px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20992=[""].join("\n");
var outline_f20_32_20992=null;
var title_f20_32_20993="Area of vulva to be grafted";
var content_f20_32_20993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skinning vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Raw area to be grafted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20993=[""].join("\n");
var outline_f20_32_20993=null;
var title_f20_32_20994="Patient information: Atrial fibrillation (The Basics)";
var content_f20_32_20994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15327\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/34/37409\">",
"         Atrial fibrillation",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21542\">",
"          Signs of stroke",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/16/8451\">",
"         Patient information: Atrial flutter (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1939\">",
"         Patient information: Heart failure and atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/11/14515\">",
"         Patient information: Latest medicines to prevent blood clots (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/36/17986\">",
"         Patient information: Medicines for atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/44/2755\">",
"         Patient information: Warfarin (Coumadin) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Atrial fibrillation (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/atrial-fibrillation-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23384098\">",
"      <span class=\"h1\">",
"       What is atrial fibrillation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Atrial fibrillation is the most common heart rhythm problem people have (",
"      <a class=\"graphic graphic_figure graphicRef76873 \" href=\"UTD.htm?36/34/37409\">",
"       figure 1",
"      </a>",
"      ). The condition puts you at risk of stroke and other problems. Another term for atrial fibrillation is &ldquo;A-fib.&rdquo;",
"     </p>",
"     <p>",
"      In people with A-fib, the electrical signals that control the heartbeat become abnormal. As a result, the top two chambers of the heart stop pumping effectively, and blood that should move out of these chambers gets left behind. As the blood pools, it can start to form clots. These clots can travel up to the brain through the blood vessels, and cause strokes.",
"     </p>",
"     <p>",
"      In some people, A-fib never goes away. In others, A-fib can come and go. If you had one or more bouts of A-fib, but have a normal heart rhythm now, ask your doctor what you can do to keep A-fib from coming back. Some people can reduce their chances of having A-fib again by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Controlling their blood pressure",
"       </li>",
"       <li>",
"        Not drinking a lot of alcohol in one sitting (limit to 1 to 2 drinks in one day)",
"       </li>",
"       <li>",
"        Cutting down on caffeine",
"       </li>",
"       <li>",
"        Getting treatment for an overactive thyroid gland",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23384105\">",
"      <span class=\"h1\">",
"       What are the symptoms of atrial fibrillation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with A-fib have no symptoms. When symptoms do occur, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling as though your heart is racing, skipping beats, or beating out of sync",
"       </li>",
"       <li>",
"        Mild chest &ldquo;tightness&rdquo; or pain",
"       </li>",
"       <li>",
"        Feeling lightheaded, dizzy, or like you might pass out",
"       </li>",
"       <li>",
"        Having trouble breathing, especially with exercise",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23384112\">",
"      <span class=\"h1\">",
"       Is there a test for atrial fibrillation?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have A-fib, he or she will probably do a test called an electrocardiogram. This test, also known as an &ldquo;ECG&rdquo; or &ldquo;EKG,&rdquo; measures the electrical activity in your heart.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23384119\">",
"      <span class=\"h1\">",
"       How is atrial fibrillation treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment can include one or more of these:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to control the speed or rhythm of the heartbeat",
"       </li>",
"       <li>",
"        Medicines to keep clots from forming",
"       </li>",
"       <li>",
"        A treatment called &ldquo;cardioversion&rdquo; that involves applying a mild electrical current to the heart to fix its rhythm",
"       </li>",
"       <li>",
"        Treatments called &ldquo;ablation,&rdquo; which use heat (&ldquo;radiofrequency ablation&rdquo;) or cold (&ldquo;cryoablation&rdquo;) to destroy the small part of the heart that is sending abnormal electrical signals",
"       </li>",
"       <li>",
"        A device called a pacemaker that is implanted in your body and sends electrical signals to the heart to control the heartbeat",
"       </li>",
"       <li>",
"        Surgery to create scar tissue in the heart to block the flow of electrical signals",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23384126\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with A-fib are able to live fairly normal lives. Still, it is important that you take the medicines your doctor prescribes every day. Taking your medicines as directed can help reduce the chances that your A-fib will cause a stroke. It&rsquo;s also a good idea to learn what the signs and symptoms of a stroke are (",
"      <a class=\"graphic graphic_figure graphicRef73487 \" href=\"UTD.htm?21/2/21542\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23384203\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"       Patient information: Atrial flutter (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"       Patient information: Heart failure and atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=see_link\">",
"       Patient information: Medicines for atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=see_link\">",
"       Patient information: Latest medicines to prevent blood clots (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?20/32/20994?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15327 Version 7.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20994=[""].join("\n");
var outline_f20_32_20994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23384098\">",
"      What is atrial fibrillation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23384105\">",
"      What are the symptoms of atrial fibrillation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23384112\">",
"      Is there a test for atrial fibrillation?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23384119\">",
"      How is atrial fibrillation treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23384126\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23384203\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15327\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/34/37409\">",
"      Atrial fibrillation",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/2/21542\">",
"       Signs of stroke",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=related_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/11/14515?source=related_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/36/17986?source=related_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_32_20995="Tethered cord syndrome";
var content_f20_32_20995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tethered cord syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    T2 sagittal magnetic resonance imaging (MRI) study&nbsp;of a patient with tethered cord syndrome (TCS). One can see the thickened filum (arrow) and the low-lying conus (asterisk) that are often seen, yet are not necessary, for this diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Chaouki El-Khoury, BS, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20995=[""].join("\n");
var outline_f20_32_20995=null;
var title_f20_32_20996="Erythroplasia of Queyrat";
var content_f20_32_20996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythroplasia of Queyrat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20996=[""].join("\n");
var outline_f20_32_20996=null;
var title_f20_32_20997="Paregoric: Drug information";
var content_f20_32_20997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paregoric: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/46/4837?source=see_link\">",
"    see \"Paregoric: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/61/43988?source=see_link\">",
"    see \"Paregoric: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diarrhea:",
"     </b>",
"     Oral: 5-10 mL 1-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F206421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/61/43988?source=see_link\">",
"      see \"Paregoric: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Diarrhea:",
"     </b>",
"     Oral: Children: 0.25-0.5 mL/kg 1-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: Morphine equivalent 2 mg/5 mL (473 mL) [contains ethanol &le;47.7% and benzoic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F206427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea or relief of pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Camphorated tincture of opium is an error-prone synonym (mistaken as opium tincture)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paregoric may be confused with Percogesic&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Use care when prescribing opium tincture; each mL contains the equivalent of morphine 10 mg; paregoric contains the equivalent of morphine 0.4 mg/mL",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, peripheral vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS depression, dizziness, drowsiness, headache, increased intracranial pressure, insomnia, malaise, mental depression, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, biliary tract spasm, constipation, nausea, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Decreased urination, ureteral spasms, urinary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Increased liver function tests",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Physical and psychological dependence, histamine release",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to opium or any component of the formulation; diarrhea caused by poisoning until the toxic material has been removed",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioid agonist toxicities: Opium shares the toxic potentials of opiate agonists, and precautions of opiate agonist therapy should be observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some preparations contain sulfites which may cause allergic reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Infants &lt;3 months of age are more susceptible to respiratory depression; use with caution and generally in reduced doses in this age group.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F206409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to morphine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F206405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information regarding use while breast-feeding is based on experience with morphine. Refer to morphine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tincture",
"     </b>",
"     (Paregoric Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/5 mL (473 mL): $313.45",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases smooth muscle tone in GI tract, decreases motility and peristalsis, diminishes digestive secretions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In terms of opium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as morphine glucuronide conjugates and unchanged drug - morphine, codeine, papaverine, etc)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Calabrese JR and Gulledge AD, &ldquo;The Neonatal Narcotic Abstinence Syndrome: A Brief Review,&rdquo;",
"      <i>",
"       Can J Psychiatry",
"      </i>",
"      , 1985, 30(8):623-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/32/20997/abstract-text/3910213/pubmed\" id=\"3910213\" target=\"_blank\">",
"        3910213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kraus DM and Pham JT, &ldquo;Neonatal Therapy,&rdquo;",
"      <i>",
"       Applied Therapeutics: The Clinical Use of Drugs",
"      </i>",
"      , 9th ed, Koda-Kimble MA, Young LY, Kradjan WA, et al, eds, Baltimore, MD: Lippincott Williams &amp; Wilkins, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M and Spino M, &ldquo;Neonatal Withdrawal Syndrome: Associated Drugs and Pharmacologic Management,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1993, 13(3):202-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/32/20997/abstract-text/8321734/pubmed\" id=\"8321734\" target=\"_blank\">",
"        8321734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/32/20997/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9740 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-996A9847C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20997=[""].join("\n");
var outline_f20_32_20997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206425\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206414\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206421\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206415\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206397\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206382\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206427\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206398\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206433\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206423\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206401\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206386\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299824\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206391\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206409\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206393\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079700\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206417\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206405\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323617\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206385\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206400\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9740\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9740|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/46/4837?source=related_link\">",
"      Paregoric: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/61/43988?source=related_link\">",
"      Paregoric: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_32_20998="Diclofenac (systemic): Patient drug information";
var content_f20_32_20998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diclofenac (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/43/8890?source=see_link\">",
"     see \"Diclofenac (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=see_link\">",
"     see \"Diclofenac (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cambia&trade;;",
"     </li>",
"     <li>",
"      Cataflam&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg;-XR;",
"     </li>",
"     <li>",
"      Zipsor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8016832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diclo Rapide&reg;;",
"     </li>",
"     <li>",
"      Apo-Diclo&reg;;",
"     </li>",
"     <li>",
"      Apo-Diclo&reg; SR&reg;;",
"     </li>",
"     <li>",
"      Ava-Diclofenac;",
"     </li>",
"     <li>",
"      Ava-Diclofenac SR;",
"     </li>",
"     <li>",
"      Cambia&reg;;",
"     </li>",
"     <li>",
"      Cataflam&reg;;",
"     </li>",
"     <li>",
"      Diclofenac ECT;",
"     </li>",
"     <li>",
"      Diclofenac Sodium;",
"     </li>",
"     <li>",
"      Diclofenac Sodium SR;",
"     </li>",
"     <li>",
"      Diclofenac SR;",
"     </li>",
"     <li>",
"      Dom-Diclofenac;",
"     </li>",
"     <li>",
"      Dom-Diclofenac SR;",
"     </li>",
"     <li>",
"      NTP-Diclofenac;",
"     </li>",
"     <li>",
"      NTP-Diclofenac SR;",
"     </li>",
"     <li>",
"      Nu-Diclo;",
"     </li>",
"     <li>",
"      Nu-Diclo-SR;",
"     </li>",
"     <li>",
"      PMS-Diclofenac;",
"     </li>",
"     <li>",
"      PMS-Diclofenac SR;",
"     </li>",
"     <li>",
"      PMS-Diclofenac-K;",
"     </li>",
"     <li>",
"      PRO-Diclo-Rapide;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac Rapide;",
"     </li>",
"     <li>",
"      Sandoz-Diclofenac SR;",
"     </li>",
"     <li>",
"      Teva-Diclofenac;",
"     </li>",
"     <li>",
"      Teva-Diclofenac K;",
"     </li>",
"     <li>",
"      Teva-Diclofenac SR;",
"     </li>",
"     <li>",
"      Voltaren Rapide&reg;;",
"     </li>",
"     <li>",
"      Voltaren SR&reg;;",
"     </li>",
"     <li>",
"      Voltaren&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701936",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diclofenac or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablets and capsules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705498",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Packets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749850",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 1 hour after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2789822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Empty contents of packet into 2 to 4 tablespoons (30 to 60 mL) of water and drink it right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11657 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20998=[""].join("\n");
var outline_f20_32_20998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016831\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027058\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027060\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027059\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027064\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027065\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027067\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027062\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027063\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027068\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027069\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/63/15348?source=related_link\">",
"      Diclofenac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10036?source=related_link\">",
"      Diclofenac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/43/8890?source=related_link\">",
"      Diclofenac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=related_link\">",
"      Diclofenac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=related_link\">",
"      Diclofenac (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=related_link\">",
"      Diclofenac (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=related_link\">",
"      Diclofenac (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_32_20999="Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins";
var content_f20_32_20999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Bruce Furie, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Beth A Bouchard, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Barbara C Furie, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/20999/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/32/20999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin K is a cofactor for the enzymatic conversion of glutamic acid (Glu) residues to gamma-carboxyglutamic acid (Gla) in vitamin K-dependent proteins, via a vitamin K-dependent gamma-glutamyl carboxylase. The importance of Gla in the function of vitamin K-dependent proteins will be reviewed here. The role of vitamin K in the synthesis of Gla is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTION OF GAMMA-CARBOXYGLUTAMIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-carboxyglutamic acid has been primarily studied in two protein families: the vitamin K-dependent blood coagulation (factors VII, IX, X, and prothrombin) and regulatory (proteins C and S) proteins, and proteins of mineralized tissue (bone Gla protein and matrix Gla protein). In addition, several proteins that contain Gla domains homologous to those of blood coagulation but of unknown function have been identified. These include Gas6 and four proteins that contain transmembrane regions as well as a Gla domain.",
"   </p>",
"   <p>",
"    Gamma-carboxyglutamic acid distinguishes itself from aspartic acid and glutamic acid by containing two carboxyl groups in its side chain. The bivalent nature of Gla is similar to the immunoglobulins or fibrinogen. In these cases, a structural framework is formed via the linking of one ligand to another through a common bivalent, symmetrical molecule. As is described below, this also applies to the formation of the calcium-carboxylate network that stabilizes the Gla domains and, in the vitamin K-dependent proteins of blood coagulation, allows expression of the phospholipid binding site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Plasma proteins of blood coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vitamin K-dependent blood coagulation and regulatory proteins contain 10 to 12 Gla residues in the Gla domain, which is located within the first 40 residues of the N-termini of the mature proteins. The Gla domain, in association with the adjacent aromatic amino acid stack domain, functions as a membrane binding component of these proteins.",
"   </p>",
"   <p>",
"    Gla is an amino acid that confers metal binding properties on the vitamin K-dependent proteins. With the addition of calcium ions, these proteins undergo a structural transition that leads to exposure of a phospholipid binding site. In most cases, neither aspartic acid nor Glu will substitute for the function of Gla, emphasizing the importance of the presence of both carboxyl groups on a single amino acid.",
"   </p>",
"   <p>",
"    The inability of Glu to substitute for Gla and the importance of vitamin K are best illustrated clinically by the usefulness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .) Warfarin prevents the recycling of vitamin K from the oxidized (epoxide) to the reduced form (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    ), leading to decreased gamma-glutamyl carboxylation because of insufficient active cofactor (the hydroquinone) (",
"    <a class=\"graphic graphic_figure graphicRef61632 \" href=\"UTD.htm?39/9/40094\">",
"     figure 1",
"    </a>",
"    ). The abnormal forms of the vitamin K-dependent proteins that result from the use of warfarin are undercarboxylated, having Glu residues at some or all of the positions that are usually carboxylated (ie, Gla). These proteins are for the most part biologically inert. Thus, in patients treated with warfarin, circulating coagulant activity correlates closely with the quantity of fully carboxylated proteins remaining in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Biosynthesis of gamma-carboxyglutamic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elimination of even one Gla residue can significantly reduce the biological function of these proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, systematic mutation of individual carboxylatable Glu residues in recombinant prothrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/2\">",
"     2",
"    </a>",
"    ] or protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] has yielded molecules with modest to severe functional defects, again indicating the importance of the bifunctional Gla side chain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Prothrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The x-ray crystal structure of prothrombin fragment 1 indicates that the Gla domain is highly structured; many of the Gla side chains point inward to a linear array of internal calcium ions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/6\">",
"     6",
"    </a>",
"    ]. Several of these calcium ions are completely sequestered inside the core of the Gla domain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Factor IX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor IX Gla domain is characterized by a fold of the polypeptide backbone, similar to that seen in prothrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/7\">",
"     7",
"    </a>",
"    ]. The location of the calcium binding sites in the internal core structure is nearly identical in prothrombin and factor IX, although there are some important distinguishing features [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Factor VII",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crystal structure of the factor VII-tissue factor complex indicates that the structure of the Gla domain of factor VII in the presence of calcium ions is nearly identical to its homolog in prothrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Phospholipid membrane binding site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phospholipid membrane binding site of the vitamin K-dependent proteins is expressed on the surface of the Gla domain. X-ray structure had shown unexpected exposure of three hydrophobic residues on the surface of these proteins, suggesting a potential role for these residues in membrane interaction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/6\">",
"     6",
"    </a>",
"    ]. Site-specific mutagenesis of homologous residues in protein C interfered with the membrane binding properties of this protein, but mutation of other hydrophobic residues did not perturb membrane binding significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been concluded that calcium-induced exposure of hydrophobic amino acids in the Gla domain is critical for membrane binding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/12\">",
"     12",
"    </a>",
"    ]. Direct comparison of the structures of the calcium-stabilized form of factor IX, which binds to membranes, and the magnesium-stabilized form of factor IX, which does not, implicated residues 1 to 11 that form a loop in the Gla domain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/13\">",
"     13",
"    </a>",
"    ]. Correlation of membrane-binding properties of the vitamin K-dependent proteins with homology considerations suggests a possible alternative membrane contact site that involves residues 11, 33, and 34 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The structure of the lysophosphatidylserine binding site in the bovine prothrombin Gla domain was determined by x-ray crystallography [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/15\">",
"     15",
"    </a>",
"    ]. The serine head group binds Gla domain-bound calcium ions and Gla residues 17 and 21, fixed elements of the Gla domain fold, predicting the structural basis for phosphatidylserine specificity among Gla domains. A molecular dynamics simulation study of anionic phospholipid binding to the Gla domain of bovine fragment 1 in the presence of calcium ions has identified a second phosphatidylserine binding site with the head group bound by a Gla-bound calcium ion, Gla 30 and Lys 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/16\">",
"     16",
"    </a>",
"    ]. It can be concluded that Gla domains provide a unique mechanism for protein-phospholipid membrane interaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gla-containing proteins of mineralized tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whereas the role of Gla is well defined for the plasma coagulation proteins, its function remains less clear in",
"    <span class=\"nowrap\">",
"     proteins/peptides",
"    </span>",
"    outside of this family. There have been no successful studies to date on the structure of Gla-containing bone proteins, including osteocalcin (bone Gla protein), the most abundant osteoblast-specific noncollagenous protein, and matrix Gla protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some insights into the function of osteocalcin and matrix Gla protein have come from experimental models lacking these proteins.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteocalcin deficient mice are characterized by increased bone formation, including higher bone mass and bones of improved functional quality; these observations suggest an important role for osteocalcin in the regulation of bone remodeling [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Matrix Gla protein deficient mice suffer from spontaneous and ultimately fatal calcification of arteries and cartilage [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/18\">",
"       18",
"      </a>",
"      ], suggesting that one of the functions of this protein is to control and limit extraosseous calcification. The Gla residues in matrix Gla protein prevent osteogenic differentiation and calcification via binding and inhibition of bone morphogenetic protein-4 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/19\">",
"       19",
"      </a>",
"      ], as well as via binding to vascular smooth muscle cell-derived vesicles [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other mammalian vitamin K-dependent proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other families of vitamin K-dependent proteins described in mammalian systems are Gas6 and the proline rich Gla proteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Gas6 protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gas6 (growth-arrest-specific gene 6) has marked sequence homology in the Gla domain to the vitamin K-dependent blood coagulation and regulatory proteins, in particular protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/21\">",
"     21",
"    </a>",
"    ]. Gas6 is released from and potentiates the growth of vascular smooth muscle cells. When synthesized in the presence of warfarin and therefore lacking Gla, Gas6 demonstrates no thrombin-inducible growth potentiating activity or receptor binding ability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, Gas6 lacking the entire Gla domain is a functional growth factor. This observation suggests that the Gla domain may be a negative regulator of the structure of a growth factor domain located elsewhere on the molecule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H665134\">",
"    <span class=\"h3\">",
"     Vitamin K-dependent single-pass integral membrane proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;This family of four proteins, identified by searching a database with a consensus sequence derived from analysis of known Gla domains, can be divided into two subclasses based on their gene organization and protein sequence.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proline rich Gla proteins, PRGP1 and PRGP2, are named for their",
"      <strong>",
"       p",
"      </strong>",
"      roline-",
"      <strong>",
"       r",
"      </strong>",
"      ich",
"      <strong>",
"       G",
"      </strong>",
"      la",
"      <strong>",
"       p",
"      </strong>",
"      rotein characteristic [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       T",
"      </strong>",
"      rans",
"      <strong>",
"       m",
"      </strong>",
"      embrane",
"      <strong>",
"       G",
"      </strong>",
"      la proteins, TMG3 and TMG4, were subsequently identified [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these proteins are expressed variably in fetal and adult tissue. While their functions are unknown, all of these proteins contain the PPXY motif involved in diverse cellular functions. The gene for TMG4 is one of those deleted in the 11p14-p12 chromosome region deletion associated with WAGR syndrome and falls into the linkage region of 11p13-p12 as an autism candidate gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gamma-glutamyl carboxylase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vitamin K-dependent gamma-glutamyl carboxylase, which converts Glu residues to Gla, has sequence homology with the region of matrix Gla protein containing the gamma-carboxylation recognition site [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/26\">",
"     26",
"    </a>",
"    ]. Under some conditions, the carboxylase can become carboxylated, although the role of Gla in this enzyme remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Protein Z",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein Z is a 62,000 molecular weight vitamin K-dependent plasma glycoprotein whose structure is similar to coagulation factors VII, IX, X, and proteins C and S [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/28\">",
"     28",
"    </a>",
"    ]. Protein Z and a protein Z-dependent protease inhibitor (ZPI) appear to serve as cofactors for the inhibition of activated factor X and activated factor XI by a number of different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. ZPI inhibition of factor Xa bound to phospholipid membranes, but not in solution, is dependent upon an interaction between the Gla domains of protein Z and factor Xa [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/32\">",
"     32",
"    </a>",
"    ]. Deficiencies of protein Z or ZPI, as with deficiencies of proteins C and S, might therefore result in a prothrombotic state (eg, arterial thrombosis, pregnancy complications, venous thromboembolism) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/33-38\">",
"     33-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In support of this supposition are the following highly preliminary observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein Z deficiency dramatically increases the severity of the prothrombotic phenotype of factor V Leiden in a transgenic mouse model [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/28\">",
"       28",
"      </a>",
"      ]. Similarly, protein Z deficiency or specific polymorphisms within the protein Z gene appear to influence clinical symptoms of thromboembolism in human subjects with factor V Leiden [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a comparison of 200 women with one unexplained primary episode of early fetal loss (10th to 15th week of gestation) and 200 controls who had normal pregnancies, protein Z deficiency was significantly more common in the women with fetal loss (22 versus 4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two studies, nonsense mutations of the ZPI gene were found in a significantly higher percent of patients with thrombosis compared with controls, with odds ratios of 5.7 and 3.3, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/31,42\">",
"       31,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationships between protein Z levels and haplotypes and ischemic stroke, Sneddon's syndrome, and atherosclerotic disease are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/43-49\">",
"     43-49",
"    </a>",
"    ]. The significance of low levels of protein Z in patients with antiphospholipid antibodies is similarly unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H665166\">",
"    <span class=\"h3\">",
"     Gla-rich proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gla-rich protein (GRP), so-named because it contains the highest Gla content of any known protein (16 of 74 residues), was identified in the calcified cartilage of the adriatic sturgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/52\">",
"     52",
"    </a>",
"    ]. The Gla containing region of GRP is not homologous to any other known Gla containing protein. GRP has orthologs in all taxonomic groups of vertebrates. GRP mRNA was found in virtually all rat and sturgeon tissue with the highest levels in cartilage and bone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/20999/abstract/52\">",
"     52",
"    </a>",
"    ]. The protein is expressed in chondrocytes, chondroblasts, osteocytes and osteoblasts. The function of this protein is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reprinted and adapted with permission from The American Society of Hematology. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gamma-carboxyglutamic acid. Blood 1999; 93:1798.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22600124\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin K is a cofactor for the conversion of glutamic acid (Glu) residues to gamma-carboxyglutamic acid (Gla) in vitamin K-dependent proteins, via a vitamin K-dependent gamma-glutamyl carboxylase (",
"    <a class=\"graphic graphic_figure graphicRef61632 \" href=\"UTD.htm?39/9/40094\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\", section on 'Biosynthesis of gamma-carboxyglutamic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gla is an amino acid that confers metal binding properties on the vitamin K-dependent proteins. With the addition of calcium ions, these proteins undergo a structural transition that leads to exposure of a phospholipid binding site. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Function of gamma-carboxyglutamic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coagulation factors which require Gla for their function include prothrombin (factor II) and factors VII, IX, and X, as well as proteins C and S. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Function of gamma-carboxyglutamic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other Gla-requiring proteins (eg, the bone and matrix Gla proteins, protein Z) are discussed above. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gla-containing proteins of mineralized tissue'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Other mammalian vitamin K-dependent proteins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/1\">",
"      Blanchard RA, Furie BC, Kruger SF, et al. Immunoassays of human prothrombin species which correlate with functional coagulant activities. J Lab Clin Med 1983; 101:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/2\">",
"      Ratcliffe JV, Furie B, Furie BC. The importance of specific gamma-carboxyglutamic acid residues in prothrombin. Evaluation by site-specific mutagenesis. J Biol Chem 1993; 268:24339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/3\">",
"      Zhang L, Jhingan A, Castellino FJ. Role of individual gamma-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood 1992; 80:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/4\">",
"      Zhang L, Castellino FJ. The contributions of individual gamma-carboxyglutamic acid residues in the calcium-dependent binding of recombinant human protein C to acidic phospholipid vesicles. J Biol Chem 1993; 268:12040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/5\">",
"      Jhingan A, Zhang L, Christiansen WT, Castellino FJ. The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma. Biochemistry 1994; 33:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/6\">",
"      Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/7\">",
"      Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry 1995; 34:12126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/8\">",
"      Huang M, Furie BC, Furie B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody. J Biol Chem 2004; 279:14338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/9\">",
"      Shikamoto Y, Morita T, Fujimoto Z, Mizuno H. Crystal structure of Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding protein. J Biol Chem 2003; 278:24090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/10\">",
"      Banner DW, D'Arcy A, Ch&egrave;ne C, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/11\">",
"      Christiansen WT, Jalbert LR, Robertson RM, et al. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid Vesicles. Biochemistry 1995; 34:10376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/12\">",
"      Sunnerhagen M, Fors&eacute;n S, Hoffr&eacute;n AM, et al. Structure of the Ca(2+)-free Gla domain sheds light on membrane binding of blood coagulation proteins. Nat Struct Biol 1995; 2:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/13\">",
"      Freedman SJ, Blostein MD, Baleja JD, et al. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 1996; 271:16227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/14\">",
"      McDonald JF, Shah AM, Schwalbe RA, et al. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997; 36:5120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/15\">",
"      Huang M, Rigby AC, Morelli X, et al. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat Struct Biol 2003; 10:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/16\">",
"      Rodr&iacute;guez Y, Mezei M, Osman R. The PT1-Ca2+ Gla domain binds to a membrane through two dipalmitoylphosphatidylserines. A computational study. Biochemistry 2008; 47:13267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/17\">",
"      Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/18\">",
"      Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/19\">",
"      Yao Y, Shahbazian A, Bostr&ouml;m KI. Proline and gamma-carboxylated glutamate residues in matrix Gla protein are critical for binding of bone morphogenetic protein-4. Circ Res 2008; 102:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/20\">",
"      Schurgers LJ, Spronk HM, Skepper JN, et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 2007; 5:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/21\">",
"      Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13:4976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/22\">",
"      Nakano T, Kawamoto K, Kishino J, et al. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 1997; 323 ( Pt 2):387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/23\">",
"      Kulman JD, Harris JE, Haldeman BA, Davie EW. Primary structure and tissue distribution of two novel proline-rich gamma-carboxyglutamic acid proteins. Proc Natl Acad Sci U S A 1997; 94:9058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/24\">",
"      Kulman JD, Harris JE, Xie L, Davie EW. Identification of two novel transmembrane gamma-carboxyglutamic acid proteins expressed broadly in fetal and adult tissues. Proc Natl Acad Sci U S A 2001; 98:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/25\">",
"      Xu S, Han JC, Morales A, et al. Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism. Cytogenet Genome Res 2008; 122:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/26\">",
"      Price PA, Williamson MK. Substrate recognition by the vitamin K-dependent gamma-glutamyl carboxylase: identification of a sequence homology between the carboxylase and the carboxylase recognition site in the substrate. Protein Sci 1993; 2:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/27\">",
"      Berkner KL, Pudota BN. Vitamin K-dependent carboxylation of the carboxylase. Proc Natl Acad Sci U S A 1998; 95:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/28\">",
"      Yin ZF, Huang ZF, Cui J, et al. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci U S A 2000; 97:6734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/29\">",
"      Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci U S A 1998; 95:9250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/30\">",
"      Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96:3049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/31\">",
"      Van de Water N, Tan T, Ashton F, et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004; 127:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/32\">",
"      Rezaie AR, Bae JS, Manithody C, et al. Protein Z-dependent protease inhibitor binds to the C-terminal domain of protein Z. J Biol Chem 2008; 283:19922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/33\">",
"      Broze GJ Jr. Protein-Z and thrombosis. Lancet 2001; 357:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/34\">",
"      Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/35\">",
"      Gris JC, Amadio C, Mercier E, et al. Anti-protein Z antibodies in women with pathologic pregnancies. Blood 2003; 101:4850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/36\">",
"      Corral J, Gonz&aacute;lez-Conejero R, Hern&aacute;ndez-Espinosa D, Vicente V. Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol 2007; 137:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/37\">",
"      Zhang J, Tu Y, Lu L, et al. Protein Z-dependent protease inhibitor deficiency produces a more severe murine phenotype than protein Z deficiency. Blood 2008; 111:4973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/38\">",
"      Sofi F, Cesari F, Abbate R, et al. A meta-analysis of potential risks of low levels of protein Z for diseases related to vascular thrombosis. Thromb Haemost 2010; 103:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/39\">",
"      Kemkes-Matthes B, Nees M, K&uuml;hnel G, et al. Protein Z influences the prothrombotic phenotype in Factor V Leiden patients. Thromb Res 2002; 106:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/40\">",
"      Kemkes-Matthes B, Matthes KJ, Souri M, et al. R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation. Br J Haematol 2005; 128:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/41\">",
"      Gris JC, Qu&eacute;r&eacute; I, Dechaud H, et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood 2002; 99:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/42\">",
"      Corral J, Gonz&aacute;lez-Conejero R, Soria JM, et al. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood 2006; 108:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/43\">",
"      Vasse M, Guegan-Massardier E, Borg JY, et al. Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet 2001; 357:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/44\">",
"      Kobelt K, Biasiutti FD, Mattle HP, et al. Protein Z in ischaemic stroke. Br J Haematol 2001; 114:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/45\">",
"      Mushunje A, Zhou A, Huntington JA, et al. Antithrombin 'DREUX' (Lys 114Glu): a variant with complete loss of heparin affinity. Thromb Haemost 2002; 88:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/46\">",
"      Ayoub N, Esposito G, Barete S, et al. Protein Z deficiency in antiphospholipid-negative Sneddon's syndrome. Stroke 2004; 35:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/47\">",
"      Sofi F, Cesari F, Pratesi G, et al. Low protein Z levels in patients with peripheral arterial disease. Thromb Haemost 2007; 98:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/48\">",
"      Nowak-G&ouml;ttl U, Fr&ouml;hlich B, Thedieck S, et al. Association of the protein Z ATG haplotype with symptomatic nonvascular stroke or thromboembolism in white children: a family-based cohort study. Blood 2009; 113:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/49\">",
"      Sofi F, Cesari F, Tu Y, et al. Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost 2009; 7:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/50\">",
"      Steffano B, Forastiero R, Martinuzzo M, Kordich L. Low plasma protein Z levels in patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis 2001; 12:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/51\">",
"      McColl MD, Deans A, Maclean P, et al. Plasma protein Z deficiency is common in women with antiphospholipid antibodies. Br J Haematol 2003; 120:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/20999/abstract/52\">",
"      Viegas CS, Simes DC, Laiz&eacute; V, et al. Gla-rich protein (GRP), a new vitamin K-dependent protein identified from sturgeon cartilage and highly conserved in vertebrates. J Biol Chem 2008; 283:36655.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1313 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-BC0FF6A85B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_20999=[""].join("\n");
var outline_f20_32_20999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22600124\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTION OF GAMMA-CARBOXYGLUTAMIC ACID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Plasma proteins of blood coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Prothrombin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Factor IX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Factor VII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Phospholipid membrane binding site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gla-containing proteins of mineralized tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other mammalian vitamin K-dependent proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Gas6 protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H665134\">",
"      - Vitamin K-dependent single-pass integral membrane proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gamma-glutamyl carboxylase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Protein Z",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H665166\">",
"      - Gla-rich proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22600124\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1313\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1313|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/9/40094\" title=\"figure 1\">",
"      Vitamin K pathway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_32_21000="Treatment and prognosis of pediatric multiple sclerosis";
var content_f20_32_21000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of pediatric multiple sclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/21000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/21000/contributors\">",
"     Timothy E Lotze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/21000/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/21000/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/21000/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/21000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/21000/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/32/21000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple sclerosis (MS) is typically considered to be a disease of young adults. However, pediatric MS, defined as onset of MS before the age of 18, is increasingly recognized and accounts for approximately 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/1\">",
"     1",
"    </a>",
"    ]. This disorder was previously known as early onset MS (EOMS) and juvenile MS.",
"   </p>",
"   <p>",
"    Since pediatric MS is rare, clinicians who see a child with recurrent episodes of acute neurologic symptoms and white matter lesions on brain magnetic resonance imaging (MRI) might initially consider a differential diagnosis that includes leukodystrophies, vasculopathies, sarcoidosis, lymphoma, mitochondrial defects, and other metabolic disorders, rather than MS. Given the availability of disease modifying therapies for MS and the impact on future prognosis, it is important to consider the possibility of pediatric MS in all children with white matter disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=see_link\">",
"     \"Differential diagnosis of acute central nervous system demyelination in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis and treatments for children with MS are different from those of the more common adult form, and to a large extent are understudied. This topic will review the treatment and prognosis of pediatric MS. Some of the references on therapy refer to adult patients, since data are limited in pediatric MS and it is assumed that the disease response is likely to be similar.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical features, and diagnosis of pediatric MS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression of disability due to multiple sclerosis (MS) is highly variable, but accumulating data suggest that progression is slow in most adults with MS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H36#H36\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Rate of disability progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several observational studies have found that a younger age at MS onset is associated with slower disease progression in terms of disability (",
"    <a class=\"graphic graphic_figure graphicRef71819 \" href=\"UTD.htm?18/9/18591\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Although not definitive, some data suggest that individuals with pediatric-onset MS have a paradoxically higher annualized relapse rate than those with adult-onset MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Nevertheless, patients with pediatric-onset MS reach disability landmarks at younger ages than those with adult onset MS. One of the largest natural history studies of pediatric MS followed a cohort of 394 patients from France and Belgium who were 16 years old or younger at MS onset [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/5\">",
"     5",
"    </a>",
"    ]. These were compared with 1775 patients who were older than 16 at MS onset. The following results were reported for patients with pediatric onset MS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated median time from disease onset to the assignment of a Kurtzke Disability Status Score of 6 (ie, assistance needed for walking) was 29 years (95% CI 27-33), and the corresponding median age was 42 years (approximately 10 years younger than the estimated median age for adult onset MS)",
"     </li>",
"     <li>",
"      The estimated median time from disease onset to conversion to secondary progression was 28 years (approximately 10 years longer than adult onset MS), and the corresponding median age was 41 years (approximately 10 years younger than adult onset MS)",
"     </li>",
"     <li>",
"      A higher relapse rate during the first two years of disease was associated with an increased rate of disability",
"     </li>",
"     <li>",
"      A progressive course at MS onset occurred in only 2 percent of children, and was associated with a shorter time to reach irreversible disability",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF ACUTE ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the mainstay for treatment of acute multiple sclerosis (MS) attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/9\">",
"     9",
"    </a>",
"    ]. They rapidly decrease inflammation and hasten recovery from an acute MS attack.",
"   </p>",
"   <p>",
"    Pulse intravenous (IV)",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    20 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given once daily for five days is a typical regimen used to treat an acute attack of MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/9\">",
"     9",
"    </a>",
"    ]. No further glucocorticoids are given for patients who demonstrate complete recovery of their symptoms. However, a tapering oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    course can be used for patients with residual disability, starting with prednisone 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and decreasing by 5 mg every two days.",
"   </p>",
"   <p>",
"    For patients who show recurrence of symptoms during the glucocorticoid taper, retreatment with IV",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (20 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given once daily for five days) is a reasonable option. Intravenous immune globulin (IVIG) can also be given in this setting and in the occasional patient who fails to respond to glucocorticoids. The usual dose of IVIG is 400",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INTERFERONS AND GLATIRAMER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulatory agents are utilized for long-term treatment of multiple sclerosis (",
"    <a class=\"graphic graphic_table graphicRef81947 \" href=\"UTD.htm?4/60/5067\">",
"     table 1",
"    </a>",
"    ). These agents, which include interferon beta drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    , reduce the frequency of clinical relapses in adults with the relapsing form of multiple sclerosis by approximately 30 percent. They also decrease progression of disability and inflammatory lesion activity on magnetic resonance imaging (MRI) as well as prevent brain atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Interferons'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Glatiramer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There have been no randomized controlled trials evaluating immunomodulatory disease modifying therapies in pediatric MS. The literature describing the effectiveness and tolerability of these agents in children is limited to isolated case series and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Nevertheless, as in adults, interferon beta and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    appear to reduce relapse rates and possibly reduce the progression of disability in pediatric patients with MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/15\">",
"     15",
"    </a>",
"    ]. Supporting evidence comes from an observational study that evaluated 65 patients with MS who were treated during childhood or adolescence at 15 centers in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/11\">",
"     11",
"    </a>",
"    ]. The mean age at onset of MS was 12 years. There were three treatment groups: 38 children received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Avonex) once weekly, nine received glatiramer acetate, and 18 received interferon beta-1a (Rebif) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    (Betaferon) three times weekly. The mean treatment duration was 23, 33, and 41 months, respectively. The following observations were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean annualized relapse rate decreased from initial to final assessment to a similar degree in each group:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Avonex: 2.4 to 0.4",
"     </li>",
"     <li>",
"      Glatiramer: 2.8 to 0.25",
"     </li>",
"     <li>",
"      Rebif-Betaferon: 3.2 to 0.8",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean expanded disability status scale (EDSS) scores from initial to final assessment showed little or no change in each group. The mean EDSS score at baseline ranged from 0.6 to 1.6.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dose and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents are usually prescribed the full adult dose.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       Glatiramer acetate",
"      </a>",
"      : 20 mg subcutaneous injection daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       Recombinant human interferon beta-1a",
"      </a>",
"      (Avonex): 30 mcg intramuscular injection once weekly",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       Recombinant human interferon beta-1a",
"      </a>",
"      (Rebif): 22 mcg or 44 mcg subcutaneous injection three times weekly",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       Recombinant human interferon beta-1b",
"      </a>",
"      (Betaseron; Betaferon): 8 million IU subcutaneous injection every other day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children under the age of 10 years, the dose of these drugs is calculated using the child's weight in kilograms divided by 50 kg and multiplying this fraction by the adult dose. A full dose is given to children weighing &ge;50 kg.",
"   </p>",
"   <p>",
"    The most common side effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    is an erythematous skin reaction localized to the injection site. This is usually transient and resolves with continued treatment. Patients should be warned about alarming but transient idiosyncratic reactions consisting of chest pain and flushing that may occur immediately after injection.",
"   </p>",
"   <p>",
"    For patients taking interferons, the most common side effects include flu-like symptoms and headache. Transient elevations of liver aminotransferases, leukopenia, and thyroid function abnormalities (hypothyroidism more often than hyperthyroidism) can occur at the initiation of therapy. These laboratory tests should be serially monitored early in the treatment course, and intermittently thereafter. Abnormalities will often resolve with transient reduction in dosing.",
"   </p>",
"   <p>",
"    All sexually active females should be counseled on the importance of contraception because of concern for teratogenicity of these agents. Interferons are category C for pregnancy risk (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). Interferon beta treatment should be discontinued if a woman becomes pregnant or plans to become pregnant during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choosing an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend treatment with a disease modifying immunomodulatory agent for children who develop relapsing-remitting MS. Reasonable choices for therapy are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Avonex), interferon beta-1a (Rebif), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"     interferon beta-1b",
"    </a>",
"    (Betaseron). All of these agents appear to have similar effectiveness for MS, and the initial choice of disease modifying immunomodulatory agent is highly influenced by patient and family preferences.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     Interferon beta-1a",
"    </a>",
"    (30 mcg intramuscular injection, Avonex) is often preferred by patients, since injections are limited to once per week. This is particularly helpful for patients with needle phobia. However, the injection is intramuscular, and therefore less favorable to some patients.",
"   </p>",
"   <p>",
"    The use of interferon beta drugs is generally avoided in adolescents who have comorbid depression, since there is concern that these agents may exacerbate depressive symptoms. In such patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    is the preferred drug. In addition, glatiramer acetate is suggested for patients who have persistent liver function abnormalities following initiation of an interferon.",
"   </p>",
"   <p>",
"    The decision process regarding the choice of therapy must include the child and family. Counseling the family on the medications and providing them with written information to review allows them to reach an educated decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MONITORING RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both clinical and neuroimaging parameters can be used to monitor response to disease modifying MS therapy. The International Pediatric MS Study Group suggests neurologic examinations at baseline, and after initiating therapy at one, three, and six months, and every six months thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/14\">",
"     14",
"    </a>",
"    ]. In clinically stable children without attacks, yearly follow-up and neurologic examination may be sufficient.",
"   </p>",
"   <p>",
"    Independent of the patient's clinical status, ongoing disease activity on brain MRI may suggest the need for an alternate immunomodulatory agent or more aggressive treatment. While there is no firmly established consensus, comparative yearly MRIs are considered by many to be a neuroimaging measure of treatment response. Patients with a high annual relapse rate often have more frequent imaging performed.",
"   </p>",
"   <p>",
"    The International Pediatric MS Study Group suggests obtaining repeat brain MRI scans six to 12 months after the initiation of an immunomodulatory agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/14\">",
"     14",
"    </a>",
"    ]. The repeat scan is compared to the baseline scan performed prior to treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For clinically stable patients with no new T2 lesions or gadolinium enhancement, the MRI can be repeated yearly.",
"     </li>",
"     <li>",
"      For patients with several new T2 lesions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      several lesions with gadolinium enhancement on follow-up imaging, repeat MRI should be performed again in six months. Changing disease modifying therapy can be considered if the MRI continues to demonstrate a significantly increasing burden of disease, as measured by new T2",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gadolinium enhancing lesions. Refractory disease is discussed in the following section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are considered to have an inadequate response (ie, treatment failure) to disease modifying immunomodulatory agents when one or more of the following conditions are present despite ongoing therapy (ie, minimum six months on full-dose therapy and fully compliant with treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two or more relapses in a 12-month period based upon clinical or MRI data",
"     </li>",
"     <li>",
"      An increase or no reduction in relapse rate",
"     </li>",
"     <li>",
"      New T2 or contrast enhancing brain lesions on MRI compared with pre-treatment period",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with treatment failure, one reasonable strategy is to change therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are poor responders to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Avonex) can be switched to higher dose interferon &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (Betaseron) or interferon beta-1a (Rebif) &ndash; or to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"     </li>",
"     <li>",
"      Poor responders to high-dose interferon can be switched to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"     </li>",
"     <li>",
"      Poor responders to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      can be switched to one of the interferon beta drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occasional children with more aggressive disease fail to show adequate response to standard disease modifying treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    and interferons. For such patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    is an option, as discussed below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Natalizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Less appealing options include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12407?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    , for which there is some evidence of effectiveness in adults, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/62/38886?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , for which evidence is inconclusive (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of progressive multiple sclerosis in adults\", section on 'Mitoxantrone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of progressive multiple sclerosis in adults\", section on 'Cyclophosphamide'",
"    </a>",
"    ). The use of such agents in pediatric MS has not been well-studied, but they have been employed in the setting of aggressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/15\">",
"     15",
"    </a>",
"    ]. One retrospective open-label study of 17 children with refractory relapsing-remitting MS found that cyclophosphamide treatment was associated with reduced relapse rates and stabilization of disability at one year in most children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/16\">",
"     16",
"    </a>",
"    ]. Nevertheless, more than half of the children with over a year of follow-up continued to have frequent relapses and required additional second-line treatment agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Natalizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials in adults with relapsing forms of MS established the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    . However, its use is rarely associated with the development of progressive multifocal leukoencephalopathy (PML), a potentially fatal complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is approved as monotherapy for adults with relapsing-remitting MS. Data are limited regarding natalizumab in pediatric MS. One of the larger studies, from a center in Italy, reported 19 children with MS (mean age 14.6 years) who were treated with intravenous natalizumab (300 mg) every 28 days for severe active MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/17\">",
"     17",
"    </a>",
"    ]. Over a mean follow up of 15 months, natalizumab treatment was associated with suppression of clinical relapses and MRI lesion activity in all subjects; no serious adverse events occurred. The manufacturer's prescribing information states that natalizumab is not indicated for pediatric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/18\">",
"     18",
"    </a>",
"    ]. However, some pediatric MS experts note that the risk profile of natalizumab must be balanced with the potential benefits, and these should be discussed in detail with the patient and family when deciding on this therapy for children with an inadequate treatment response to first-line agents for MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    for children with aggressive or fulminant relapsing MS that is refractory to the standard disease modifying agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    and interferon beta drugs) as long as they are willing to accept the small risk of PML associated with treatment. Natalizumab should be used as monotherapy only. Patients receiving natalizumab must be followed in a risk management program to monitor for symptoms or signs suggestive of PML. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\", section on 'Risk of progressive multifocal leukoencephalopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link&amp;anchor=H6#H6\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\", section on 'Clinical use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H123472263\">",
"    <span class=\"h2\">",
"     Mitoxantrone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/7/12407?source=see_link\">",
"     Mitoxantrone",
"    </a>",
"    is approved for use in adults with both relapsing-remitting and progressive forms of MS. However, because of cardiac toxicity, the increased incidence of leukemia, and the somewhat limited evidence of benefit, mitoxantrone is reserved for patients with rapidly advancing disease who have failed other therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/19\">",
"     19",
"    </a>",
"    ]. Because of its risk profile, a number of experts discourage the use of mitoxantrone in children [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168646148\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of newer disease modifying drugs are effective for the treatment of relapsing-remitting MS in adults, as demonstrated in randomized controlled trials. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/11/26806?source=see_link\">",
"       Fingolimod",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H26726955#H26726955\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Fingolimod'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"       Teriflunomide",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H104685535#H104685535\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Teriflunomide'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      BG-12 (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       Alemtuzumab",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Alemtuzumab'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/11/26806?source=see_link\">",
"     Fingolimod",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8918?source=see_link\">",
"     teriflunomide",
"    </a>",
"    are oral drugs approved for the treatment of adults with relapsing forms of MS in many countries, while oral BG-12 and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    may receive regulatory approval in 2013. However, these agents have not been evaluated for children with MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/15\">",
"     15",
"    </a>",
"    ]. Therefore, we suggest not using them for children until further data are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While immunomodulatory agents have dramatically altered the long-term treatment strategy for MS, management of daily symptoms remains a cornerstone to improving quality of life in these patients. Symptoms directly related to demyelination and its effects require a comprehensive evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is one of the most common complaints of patients with MS (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link&amp;anchor=H116553222#H116553222\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\", section on 'Fatigue and depression'",
"    </a>",
"    ). Recognition of depression as causative for fatigue is important in this patient population and requires consultation with a psychiatrist experienced with MS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Depression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most common type of fatigue encountered in MS is related directly to the disease and is often called lassitude or MS-related fatigue. It is described as an overwhelming feeling of tiredness in those who have done little and are not depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21000/abstract/21\">",
"     21",
"    </a>",
"    ]. Occupational therapy assessment can be useful to improve any mitigating circumstances contributing to the fatigue.",
"   </p>",
"   <p>",
"    Pharmacologic agents for fatigue include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"     amantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=see_link\">",
"     modafinil",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"     methylphenidate",
"    </a>",
"    . Amantadine or modafinil are typically used as first-line treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"       Amantadine",
"      </a>",
"      is given at 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      two times a day (maximum 150",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for children under 40 kg or younger than 10 years of age. Older children and adults are prescribed 100 mg twice daily, increasing up to a total daily dose of 400 mg if needed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=see_link\">",
"       Modafinil",
"      </a>",
"      is started at 50 to 100 mg once a day for children under 10 years. Older children begin with 100 mg daily and the dose is increased as needed up to 300 mg daily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10890?source=see_link\">",
"       Methylphenidate",
"      </a>",
"      and similar amphetamines are prescribed at doses typically used for the treatment of attention deficit disorder. Long-acting preparations of these medications are preferred. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=see_link&amp;anchor=H2#H2\">",
"       \"Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents\", section on 'Stimulants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      is usually started at 10 mg every other day for two weeks and then increased up to a maximum dose of 20",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for children under age 10 years and up to 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for adolescents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/63/33785?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and other antidepressants must be done with caution, given concern of increased suicidal ideation following initiation of these agents in children and adolescents treated for major depression. In addition, fatigue may be a presenting feature of major depression, and this possibility must be thoroughly investigated. Consultation with a child psychiatrist should be obtained before starting these agents if there is evidence of a mood disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children with MS develop depression (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link&amp;anchor=H116553222#H116553222\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\", section on 'Fatigue and depression'",
"    </a>",
"    ) and require consultation and treatment by a pediatric psychiatrist. Multiple sclerosis profoundly affects all aspects of the child's life, and also has significant effects on the families. It is potentially a life-long diagnosis with implications of progressive disability. In addition, children with MS must often handle the considerable burden of daily to weekly injections of immunomodulatory agents. Nevertheless, many children seem to cope with the diagnosis fairly well, while their parents and other family members often have greater difficulty. This may relate to the \"invincible\" attitude of most adolescents. The clinician should carefully note changing psychosocial dynamics of the patient and his or her family.",
"   </p>",
"   <p>",
"    The evaluation and treatment of pediatric depression is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"     \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=see_link\">",
"     \"Overview of treatment for adolescent depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive deficits in children with MS may include problems with general cognition, language, visuomotor integration, and verbal and visual memory (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=see_link&amp;anchor=H116553116#H116553116\">",
"     \"Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis\", section on 'Cognitive symptoms'",
"    </a>",
"    ). For children who are having problems with school, annual neuropsychological assessment may be useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other major problems encountered in patients with MS are muscle spasticity, pain, and bladder issues. Treatment for these conditions includes pharmaceutical intervention as well as consultation with physical and occupational therapists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=see_link\">",
"       \"Patient information: Multiple sclerosis in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/47/17138?source=see_link\">",
"       \"Patient information: Multiple sclerosis in children (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with multiple sclerosis (MS) have slow disease progression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For acute attacks of multiple sclerosis in children, we suggest intravenous (IV)",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      20 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      given once daily for five days (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Glucocorticoids can be stopped without a taper in children who demonstrate complete recovery, while a tapering oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      regimen can be used for patients with residual disability. We taper by starting oral prednisone at 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and decreasing by 5 mg every two days. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment of acute attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with acute exacerbation of MS who fail to respond to IV glucocorticoid therapy, we suggest intravenous immune globulin (IVIG) 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For children who relapse during a taper of glucocorticoids, we suggest either retreatment with IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      20 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), or IVIG 400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment of acute attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children who develop relapsing-remitting MS, we recommend treatment with a disease modifying immunomodulatory agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Reasonable choices for therapy are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Avonex), interferon beta-1a (Rebif), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (Betaseron). All of these agents appear to have similar effectiveness for MS in adult clinical trials, and the initial choice of disease modifying immunomodulatory agent is highly influenced by patient and family preferences. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Interferons and glatiramer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Choosing an agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both clinical and neuroimaging parameters can be used to monitor response to disease modifying MS therapy. Patients are considered to have an inadequate response to therapy (ie, minimum six months on full-dose therapy and fully compliant with treatment) if they develop two or more relapses in a 12-month period, an increase or no reduction in relapse rate, or new T2 or contrast enhancing brain lesions on MRI compared with the pre-treatment period. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Monitoring response to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Refractory disease'",
"      </a>",
"      above.):",
"     </li>",
"     <li>",
"      For patients with treatment failure, one strategy is to switch disease modifying therapy. As examples, patients who are poor responders to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Avonex) can be switched to higher dose interferon &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (Betaseron) or interferon beta-1a (Rebif) &ndash; or switched to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      . Poor responders to higher dose interferon can be switched to glatiramer acetate. Poor responders to glatiramer acetate can be switched to one of the interferon beta drugs. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with aggressive or fulminant relapsing MS that is refractory to the standard disease modifying agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      and interferon beta drugs) who are willing to accept the small risk of progressive multifocal leukoencephalopathy, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      and stopping treatment with standard disease modifying agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Natalizumab should be used as monotherapy only. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Natalizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic treatment of daily symptoms remains a cornerstone to improving quality of life in patients with multiple sclerosis. Fatigue is the most common complaint of patients with multiple sclerosis. Typical pharmacologic treatments include",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/20/38214?source=see_link\">",
"       modafinil",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptomatic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other prominent issues that can affect children with multiple sclerosis include depression, cognitive impairment, muscle spasticity, pain, and bladder issues. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptomatic management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/1\">",
"      Boiko A, Vorobeychik G, Paty D, et al. Early onset multiple sclerosis: a longitudinal study. Neurology 2002; 59:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/2\">",
"      Cole GF, Stuart CA. A long perspective on childhood multiple sclerosis. Dev Med Child Neurol 1995; 37:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/3\">",
"      Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/4\">",
"      Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/5\">",
"      Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/6\">",
"      Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009; 66:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/7\">",
"      Trojano M, Paolicelli D, Bellacosa A, et al. Atypical forms of multiple sclerosis or different phases of a same disease? Neurol Sci 2004; 25 Suppl 4:S323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/8\">",
"      Held U, Heigenhauser L, Shang C, et al. Predictors of relapse rate in MS clinical trials. Neurology 2005; 65:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/9\">",
"      Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol 2011; 26:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/10\">",
"      Banwell BL. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/11\">",
"      Ghezzi A, Amato MP, Capobianco M, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 2005; 11:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/12\">",
"      Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006; 66:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/13\">",
"      Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 2006; 67:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/14\">",
"      Pohl D, Waubant E, Banwell B, et al. Treatment of pediatric multiple sclerosis and variants. Neurology 2007; 68:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/15\">",
"      Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012; 18:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/16\">",
"      Makhani N, Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009; 72:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/17\">",
"      Ghezzi A, Pozzilli C, Grimaldi LM, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 2010; 75:912.",
"     </a>",
"    </li>",
"    <li>",
"     Tysabri prescriber information. www.tysabri.com/en_US/tysb/site/pdfs/TYSABRI-pi.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/19\">",
"      Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/20\">",
"      Attarian HP, Brown KM, Duntley SP, et al. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol 2004; 61:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21000/abstract/21\">",
"      Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988; 45:435.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6223 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21000=[""].join("\n");
var outline_f20_32_21000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF ACUTE ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INTERFERONS AND GLATIRAMER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dose and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choosing an agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MONITORING RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Natalizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H123472263\">",
"      Mitoxantrone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168646148\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SYMPTOMATIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6223|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/9/18591\" title=\"figure 1\">",
"      Time to sustained disability in MS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6223|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/60/5067\" title=\"table 1\">",
"      Treatment pediatric MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1352?source=related_link\">",
"      Differential diagnosis of acute central nervous system demyelination in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=related_link\">",
"      Natalizumab for relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13738?source=related_link\">",
"      Overview of treatment for adolescent depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/32/12809?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/31/40447?source=related_link\">",
"      Patient information: Multiple sclerosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/47/17138?source=related_link\">",
"      Patient information: Multiple sclerosis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14650?source=related_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_32_21001="Hyperimmunoglobulin M syndromes";
var content_f20_32_21001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperimmunoglobulin M syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/21001/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/21001/contributors\">",
"     Luigi D Notarangelo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/21001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/21001/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/32/21001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/32/21001/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/32/21001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4462576\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperimmunoglobulin M (hyper-IgM or HIGM) syndromes include a heterogeneous group of conditions characterized by defective class-switch recombination (CSR), resulting in normal or increased levels of serum IgM associated with deficiency of IgG, IgA, and IgE and poor antibody function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/1\">",
"     1",
"    </a>",
"    ]. Hyper-IgM syndrome includes several genetically-determined diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], but may also be secondary to congenital rubella syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/4\">",
"     4",
"    </a>",
"    ], use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , T cell leukemia, or lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic discusses in detail only genetically-determined forms of hyper-IgM syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462584\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maturation of antibody responses is marked by a series of events that include (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class-switch recombination (CSR, also called class-switching), whereby the immunoglobulin mu heavy chain is replaced by other heavy chain isotypes with distinct biologic properties, resulting in production of immunoglobulin isotypes other than IgM.",
"     </li>",
"     <li>",
"      Somatic hypermutation (SHM), by which somatic mutations are introduced in the variable region of actively transcribed immunoglobulin genes, thereby allowing production of high-affinity antibodies.",
"     </li>",
"     <li>",
"      Generation of memory B cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Costimulatory signals provided by T cells play a critical role during CSR. Activated CD4",
"    <sup>",
"     +",
"    </sup>",
"    follicular helper T cells express CD40 ligand (CD40L or CD154) and secrete various cytokines upon antigen recognition. Cytokines released by activated CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells bind to cognate receptors expressed on the surface of B cells and prompt CSR to specific immunoglobulin isotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. CD40L binds CD40 that is constitutively expressed by B cells. CD40 ligation in B cells promotes activation of tumor necrosis factor receptor-associated factor (TRAF) molecules and the nuclear factor-kappa-B (NF-&kappa;B) signaling pathway, allowing expression of NF-&kappa;B-dependent genes, such as the activation-induced cytidine deaminase (",
"    <em>",
"     AICDA",
"    </em>",
"    ) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/6\">",
"     6",
"    </a>",
"    ]. Activation-induced cytidine deaminase (AID) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/7\">",
"     7",
"    </a>",
"    ] and uracil N-glycosylase (UNG) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/8\">",
"     8",
"    </a>",
"    ] are two enzymes involved in CSR. Mismatched repair (MMR) proteins, including the post-meiotic segregation increased 2 (PMS2) protein, are also involved in the process [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AID also initiates SHM, with deamination of cytidine residues in the variable region of immunoglobulin genes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/10\">",
"     10",
"    </a>",
"    ]. All forms of hyper-IgM syndrome are characterized by defective CSR. Some forms also have impairment of SHM, with production of low-affinity antibodies (",
"    <a class=\"graphic graphic_table graphicRef86094 \" href=\"UTD.htm?2/52/2893\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaired CSR in hyper-IgM syndromes are due to B cell-intrinsic abnormalities or defects that involve several types of immune cells. This difference in the pathogenesis accounts for the distinctive clinical features in the various forms of hyper-IgM syndrome.",
"   </p>",
"   <p>",
"    In particular,",
"    <em>",
"     CD40LG",
"    </em>",
"    (encoding for CD40L) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/11-15\">",
"     11-15",
"    </a>",
"    ] and",
"    <em>",
"     CD40",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/16\">",
"     16",
"    </a>",
"    ] mutations affect the interaction between activated CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells and cell types expressing CD40 (B cells, dendritic cells,",
"    <span class=\"nowrap\">",
"     monocyte/macrophages,",
"    </span>",
"    platelets, activated endothelial and epithelial cells). Thus, impairment of CSR in these disorders is part of a broader spectrum of immunologic abnormalities that also include defective T cell priming and impaired antigen-specific T cell responses, resulting in a combined immunodeficiency phenotype. In contrast,",
"    <em>",
"     AICDA",
"    </em>",
"    (encoding for activation-induced cytidine deaminase, AID) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/7\">",
"     7",
"    </a>",
"    ] and",
"    <em>",
"     UNG",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/8\">",
"     8",
"    </a>",
"    ] mutations uniquely affect B cell function and hence represent the prototypes of B cell-intrinsic abnormalities of CSR. AID plays a role in B cell tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/17\">",
"     17",
"    </a>",
"    ]. CD40L deficiency is also known as HIGM1; AID deficiency as HIGM2; CD40 deficiency as HIGM3; and UNG deficiency as HIGM5. No specific molecular defect has been identified yet in HIGM4.",
"   </p>",
"   <p>",
"    Mutations of the",
"    <em>",
"     IKBKG",
"    </em>",
"    gene (encoding for",
"    <span class=\"nowrap\">",
"     IKK-&gamma;/NEMO,",
"    </span>",
"    a regulatory component of the NF-&kappa;B signaling pathway) affect the NF-&kappa;B signaling pathway in a variety of cell types and are responsible for X-linked ectodermal dysplasia with immunodeficiency (XL-EDA-ID), whose phenotype may also include impaired CSR [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Defective CSR also occurs in patients with deficiency of PMS2 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/9\">",
"     9",
"    </a>",
"    ], a disorder characterized by an increased risk of malignancies in childhood. Finally, CSR is defective in other diseases associated with impairment of DNA repair, such as ataxia-telangiectasia and Nijmegen breakage syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/21\">",
"     21",
"    </a>",
"    ]. In some cases, patients with these diseases may show immunoglobulin abnormalities consistent with hyper-IgM syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462592\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A list of gene defects that cause hyper-IgM syndrome is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef86094 \" href=\"UTD.htm?2/52/2893\">",
"     table 1",
"    </a>",
"    ). The most common form of hyper-IgM syndrome is inherited as an X-linked trait and is due to mutations of the",
"    <em>",
"     CD40LG",
"    </em>",
"    gene, also known as",
"    <em>",
"     TNFSF5",
"    </em>",
"    . Carrier females of X-linked hyper-IgM syndrome (also known as hyper-IgM syndrome type 1, HIGM1, MIM 308230) are clinically healthy. Exceptional occurrence of the disease has been observed in females as a result of extreme lyonization (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/22\">",
"     22",
"    </a>",
"    ] that may be the consequence of chromosomal translocation involving the",
"    <em>",
"     CD40LG",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AID deficiency (also known as HIGM2, MIM 605258) is the second most common form of hyper-IgM syndrome and is inherited as an autosomal recessive trait. However, autosomal dominant inheritance has been reported in four families with a nonsense mutation in the",
"    <em>",
"     ACIDA",
"    </em>",
"    gene that affected the C-terminus of the AID protein [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. UNG deficiency (MIM 608106) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/8\">",
"     8",
"    </a>",
"    ] and CD40 deficiency (HIGM3, MIM 606843) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/16\">",
"     16",
"    </a>",
"    ] also have autosomal recessive inheritance. In addition to these genetically-defined forms, there is one variant of defective CSR downstream from S region DNA cleavage (also known as HIGM4, 608184) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/26\">",
"     26",
"    </a>",
"    ] whose molecular basis remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462600\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of hyper-IgM syndrome are rare. The estimated frequency of CD40L deficiency is 2:1,000,000 males [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27\">",
"     27",
"    </a>",
"    ]. Although no data are available on the frequency of AID deficiency, this disorder is estimated to affect fewer than 1:1,000,000 individuals. In contrast, there are only few reported cases of CD40 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/16,28-30\">",
"     16,28-30",
"    </a>",
"    ] and UNG [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/8\">",
"     8",
"    </a>",
"    ] deficiency. There is parental consanguinity in several families with autosomal recessive hyper-IgM syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462608\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical phenotype of hyper-IgM syndrome varies depending upon the nature of the genetic defect. CD40L and CD40 deficiencies are combined immunodeficiencies, whereas AID and UNG deficiencies are humoral immunodeficiencies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link\">",
"     \"Combined immunodeficiencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4468219\">",
"    <span class=\"h2\">",
"     In CD40L or CD40 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CD40L or CD40 deficiency share similar features. Here, we will refer to reports pertaining to CD40L-deficient patients, because only few CD40-deficient patients have been described.",
"   </p>",
"   <p>",
"    CD40L deficiency often presents in infancy with increased susceptibility to recurrent sinopulmonary infections (eg, pneumonia, sinusitis, and otitis media), primarily caused by encapsulated bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27,31,32\">",
"     27,31,32",
"    </a>",
"    ]. In addition, opportunistic infections, particularly with Pneumocystis, Cryptosporidium, and Histoplasma organisms, are common and may occur in the first few months of life.",
"    <em>",
"     Pneumocystis jirovecii",
"    </em>",
"    pneumonia, for example, is reported in approximately 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27,31\">",
"     27,31",
"    </a>",
"    ] and may represent the first clinical finding. Lymphadenopathy and hepatosplenomegaly are often present on physical examination.",
"   </p>",
"   <p>",
"    Chronic or protracted diarrhea occurs in one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27,31,32\">",
"     27,31,32",
"    </a>",
"    ] and may lead to failure to thrive. Infection with the parasite",
"    <em>",
"     Cryptosporidium parvum",
"    </em>",
"    is common and is associated with an increased risk of biliary tract disease.",
"    <em>",
"     C. parvum",
"    </em>",
"    infection was reported in 21 and 60 percent of CD40L-deficient patients who developed chronic diarrhea in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27\">",
"     27",
"    </a>",
"    ] and Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"     31",
"    </a>",
"    ], respectively. Sclerosing cholangitis was observed in 6 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27\">",
"     27",
"    </a>",
"    ] and 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"     31",
"    </a>",
"    ] percent of these patients. The different frequency of",
"    <em>",
"     C. parvum",
"    </em>",
"    infection and biliary tract disease in these series may reflect differences in the levels of",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    oocysts in water supplies in these regions.",
"   </p>",
"   <p>",
"    Liver disease in patients with CD40L deficiency may also be secondary to cytomegalovirus (CMV) infection. Cirrhosis and cholangiocarcinoma represent two frequent complications of",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    and CMV infection in patients with CD40L deficiency.",
"   </p>",
"   <p>",
"    Patients with CD40L deficiency are at higher risk for cryptococcus and toxoplasma infections that may affect the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31,33,34\">",
"     31,33,34",
"    </a>",
"    ]. Enteroviral meningoencephalitis and progressive multifocal leukoencephalopathy due to JC virus have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27,35,36\">",
"     27,35,36",
"    </a>",
"    ]. Among bacterial infections, cellulitis, sepsis, and osteomyelitis have been reported. Aphthous stomatitis is common.",
"   </p>",
"   <p>",
"    CD40L deficiency is associated with an increased risk of malignancies, including hepatocarcinoma, cholangiocarcinoma, and peripheral neuroectodermal tumors of the gastrointestinal tract and the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27,31,37,38\">",
"     27,31,37,38",
"    </a>",
"    ]. Lymphomas have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmune manifestations are observed in a minority of CD40L-deficient patients and include inflammatory bowel disease and cytopenias.",
"   </p>",
"   <p>",
"    Osteopenia is another feature of CD40L deficiency, and may lead to spontaneous fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4468226\">",
"    <span class=\"h2\">",
"     In AID deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical phenotype of AID deficiency is marked by recurrent sinopulmonary infections, mostly due to encapsulated bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/7,41,42\">",
"     7,41,42",
"    </a>",
"    ]. Meningitis, cellulitis, lymphadenitis, and infections of the gastrointestinal tract are also reported.",
"   </p>",
"   <p>",
"    The median onset of symptoms is two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/42\">",
"     42",
"    </a>",
"    ], but the diagnosis of an immunodeficiency is often delayed by a decade or two. [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphoid hyperplasia is a distinctive feature of AID deficiency not seen in CD40L deficiency that is characterized by paucity of lymphoid and tonsillar tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/32\">",
"     32",
"    </a>",
"    ]. Tonsillar hypertrophy is often prominent and may prompt tonsillectomy.",
"   </p>",
"   <p>",
"    Autoimmune complications occur in approximately 20 percent of patients with AID deficiency, and include cytopenias, hepatitis, inflammatory bowel disease, and arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18933964\">",
"    <span class=\"h2\">",
"     In other types of hyper-IgM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The few patients identified with UNG deficiency have a clinical phenotype that resembles that of AID deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with HIGM4 also have clinical manifestations similar to, but slightly milder than, AID deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462616\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with recurrent infections are typically evaluated for an immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory abnormalities in hyper-IgM syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Markedly reduced serum levels of IgG, IgA, and IgE",
"     </li>",
"     <li>",
"      Normal or elevated levels of serum IgM",
"     </li>",
"     <li>",
"      Lack of antibody response to protein and polysaccharide antigens",
"     </li>",
"     <li>",
"      Markedly reduced number of memory (CD27+) B cells [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Absence of switched memory (IgD-CD27+) B cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These abnormalities are observed both in patients with CD40L (or CD40) deficiency and in patients with AID and UNG deficiency. However, newborns and young infants (&lt;4 months of age) may have residual levels of serum IgG of maternal origin. In addition, residual IgG production is often present in patients with HIGM4. Occasionally, patients with CD40L deficiency may have normal or even increased IgA serum levels [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"     31",
"    </a>",
"    ], possibly as the result of CD40-independent, Toll-like receptor-dependent activation of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these disorders are collectively known as hyper-IgM syndrome, serum levels of IgM are normal or even decreased in approximately 50 percent of patients with CD40L deficiency at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutropenia occurs in two-thirds of CD40L-deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and may contribute to infections. It is often chronic or cyclic. Bone marrow examination may show a maturational arrest at the promyelocyte stage [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"     31",
"    </a>",
"    ]. Anemia is reported in 15 to 32 percent and thrombocytopenia in 4 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27,31,45\">",
"     27,31,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, patients with CD40L deficiency typically present the following immunologic abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impairment of delayed-type hypersensitivity reactions in vivo to recall antigens in most patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/1,46\">",
"       1,46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced in vitro T cell proliferation to recall antigens in approximately 60 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"       31",
"      </a>",
"      ], whereas in vitro proliferation to mitogens (eg, phytohemagglutinin, PHA) is normal",
"     </li>",
"     <li>",
"      Reduced production of Th1 cytokines upon in vitro activation of peripheral blood mononuclear cells with anti-CD3 or superantigens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lack of germinal centers (or presence of abortive germinal centers) in peripheral lymphoid tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impaired differentiation and activation of dendritic cells in response to",
"      <em>",
"       Candida",
"      </em>",
"      and other intracellular pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reduced antigen-specific T cell responses in vitro and in vivo, and the poor production of Th1 cytokines upon T cell activation, are also observed in patients with CD40 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/51\">",
"     51",
"    </a>",
"    ] and reflect defective cross-talk between activated CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells and dendritic",
"    <span class=\"nowrap\">",
"     cells/macrophages",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, no defects in T cell responses are observed in patients with AID or UNG deficiency. In addition, expansion of germinal centers is observed in peripheral lymphoid tissue from these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with HIGM4 have residual IgG production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462624\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Males with a possible diagnosis of hyper-IgM syndrome should be analyzed first for CD40L expression on the surface of in vitro activated T cells. Definitive confirmation of the diagnosis, both for CD40L deficiency and for other forms of hyper-IgM syndrome, requires mutation analysis. A list of laboratories offering testing for hyper-IgM (including protein expression, sequence analysis, prenatal diagnosis, and carrier testing) can be found at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/review/disease/hyper-IgM?db=genetests&amp;search_param=contains\">",
"     file://www.ncbi.nlm.nih.gov/sites/GeneTests/review/disease/hyper-IgM?db=genetests&amp;search_param=contains",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18934025\">",
"    <span class=\"h2\">",
"     Of CD40L deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of X-linked HIGM (CD40L deficiency) is almost certain in males with opportunistic infections and the characteristic profile of low serum levels of IgG and normal or high serum levels of IgM. In newborns and infants younger than six months of age, the diagnosis of CD40L deficiency is primarily based upon genetic testing, since reduced ability to express CD40L can occur in CD4+ lymphocytes from patients in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Confirmation of diagnosis in older children is based upon demonstration of impaired expression of CD40L on the surface of CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells upon in vitro",
"    <em>",
"    </em>",
"    activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27,54\">",
"     27,54",
"    </a>",
"    ]. Typically, this is achieved by activating peripheral mononuclear cells overnight with phorbol myristate acetate (PMA) and ionomycin, followed by staining for CD40L using anti-CD40L monoclonal antibodies and gating on CD8-negative cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=see_link&amp;anchor=H11#H11\">",
"     \"Flow cytometry for the diagnosis of primary immunodeficiencies\", section on 'Hyper IgM syndrome (HIGM)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Simultaneous staining for other T cell activation markers (CD69, CD25) must be performed to confirm proper in vitro activation. This is important when considering other conditions in the differential diagnosis, such as common variable immune deficiency (see",
"    <a class=\"local\" href=\"#H25649353\">",
"     'Differential diagnosis'",
"    </a>",
"    below). In addition, gating on CD8-negative cells is preferred over gating on CD4",
"    <sup>",
"     +",
"    </sup>",
"    lymphocytes when assessing CD40L expression on activated lymphocytes, because downregulation of CD4 expression that is typically observed upon in vitro activation might otherwise confound interpretation of the results.",
"   </p>",
"   <p>",
"    In most cases, use of anti-CD40L monoclonal antibodies readily allows identification of CD40L-deficient patients. However, some mutations permit low level cell surface expression of a nonfunctional CD40L on activated T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, patients whose clinical and immunologic phenotype is strongly suggestive for CD40L deficiency, but in whom staining with anti-CD40L monoclonal antibody is normal, should be analyzed by flow cytometry using biotinylated CD40-Ig chimeric construct (followed by reaction with fluorochrome-labeled streptavidin) or monoclonal antibodies directed against the CD40-binding epitope [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, some",
"    <em>",
"     CD40LG",
"    </em>",
"    mutations affect the intracytoplasmic tail of CD40L without disturbing cell surface expression and CD40 binding; in such cases, the diagnosis is ultimately achieved by mutation analysis.",
"   </p>",
"   <p>",
"    Final confirmation of CD40L deficiency requires mutation analysis. A variety of missense, nonsense, splice-site mutations, insertions, and deletions throughout the",
"    <em>",
"     CD40LG",
"    </em>",
"    gene have been reported, with only a few mutational hot-spots [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/45,53,55,56\">",
"     45,53,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18934039\">",
"    <span class=\"h2\">",
"     Of CD40 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with possible CD40 deficiency (eg, clinical and immunologic presentation consistent with CD40L deficiency occurring in a female or in a male with normal CD40L), the diagnosis is confirmed by analyzing CD40 expression on the surface of B cells and monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/16,30\">",
"     16,30",
"    </a>",
"    ]. Flow cytometry can be applied on freshly isolated peripheral blood mononuclear cells without further manipulation because these cells constitutively express CD40. Most patients described with this rare form of hyper-IgM syndrome have complete lack of CD40 expression at the cell surface; however, residual expression of a mutant molecule has been reported. Mutation analysis ultimately permits definitive confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18934046\">",
"    <span class=\"h2\">",
"     Of AID or UNG deficiency or HIGM4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of the diagnosis of AID deficiency (also known as HIGM2) or UNG deficiency (HIGM5) is based upon genetic testing. The molecular basis of HIGM4 remains unknown. Thus, confirmatory testing is not available for HIGM4.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25649353\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyper-IgM can be seen in patients with other immunodeficiencies, such as ataxia-telangiectasia, Nijmegen breakage syndrome, and common variable immunodeficiency. Hypomorphic mutations in recombination activating gene 2 (RAG2) can also cause a combined immunodeficiency that may occasionally present with a clinical and immunologic phenotype similar to hyper-IgM syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, there are rare reports of acquired forms of hyper-IgM associated with congenital rubella syndrome,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    therapy, T cell leukemia, and lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=see_link&amp;anchor=H4018211#H4018211\">",
"     \"Combined immunodeficiencies\", section on 'Hypomorphic RAG1 and RAG2 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327122727\">",
"    <span class=\"h2\">",
"     Ataxia-telangiectasia (AT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AT may present with hyper-IgM due to the presence of monomeric IgM. Elevated &alpha;-fetoprotein levels and presence of typical neurologic features and telangiectasias facilitate the diagnosis of AT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327122757\">",
"    <span class=\"h2\">",
"     Nijmegen breakage syndrome (NBS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased levels of serum IgM (possibly reflecting monomeric IgM molecules) have been reported in NBS. However, these patients show unique features of microcephaly, short stature, facial dysmorphisms, and progressive decline of intellectual ability that are not seen in HIGM syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/439?source=see_link\">",
"     \"Nijmegen breakage syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327122742\">",
"    <span class=\"h2\">",
"     Common variable immunodeficiency (CVID)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proportion of patients with CVID have T cell activation defects and may present with a hyper-IgM-like immunologic phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. CVID remains largely a diagnosis of exclusion. Accurate analysis of the immunologic phenotype and testing to rule out HIGM syndrome is important in the diagnostic approach to these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=see_link\">",
"     \"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=see_link\">",
"     \"Common variable immunodeficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H327122772\">",
"    <span class=\"h2\">",
"     Congenital rubella syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased levels of IgM, with variable levels of IgG, have been reported in patients with congenital rubella infection. Deafness, cataracts, and cardiac disease, clinical features that are not found in HIGM syndrome, are the classic manifestations of congenital rubella syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link&amp;anchor=H6#H6\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Humoral response'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=see_link&amp;anchor=H8#H8\">",
"     \"Congenital rubella syndrome: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462632\">",
"    <span class=\"h1\">",
"     CARRIER DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;CD40L deficiency is an X-linked disease. Random X-chromosome inactivation leads to a bimodal pattern of CD40L expression on the surface of CD8-negative (ie, CD4",
"    <sup>",
"     +",
"    </sup>",
"    ) lymphocytes from female carriers of X-linked hyper-IgM syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/60\">",
"     60",
"    </a>",
"    ]. However, mutation analysis is the method of choice to determine the carrier status in females of childbearing age belonging to families with CD40L deficiency, and should be proposed as part of genetic counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462640\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyper-IgM should be managed by an immunology specialist in addition to their primary care provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18934067\">",
"    <span class=\"h2\">",
"     CD40L and CD40 deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of CD40L or CD40 deficiency is more complex than other forms of hyper-IgM, because these defects cause combined immune deficiencies. Immune globulin replacement therapy is effective in reducing the risk of recurrent sinopulmonary infections and bronchiectasis. However, CD40L-deficient patients are at high risk of opportunistic infections and of",
"    <span class=\"nowrap\">",
"     liver/biliary",
"    </span>",
"    tract complications that reflect B cell-extrinsic defects.",
"   </p>",
"   <p>",
"    Prevention of",
"    <em>",
"     Pneumocystis jirovecii",
"    </em>",
"    pneumonia is based upon continuous prophylaxis with trimethoprim-cotrimoxazole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"     31",
"    </a>",
"    ].",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    infection represents a challenge. Several hygiene measures have been recommended to reduce the risk of such infection (",
"    <a class=\"graphic graphic_table graphicRef86095 \" href=\"UTD.htm?12/14/12523\">",
"     table 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    and azythromycin may be helpful in patients with active disease, but will rarely eradicate",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    . Azythromycin has been also proposed for prophylaxis of",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    infection, but no data are available to support long-term efficacy. The best prophylaxis to prevent",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    infection remains use of hygienic measures, such as avoiding baths in rivers, lakes, or pools. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic severe neutropenia and a history of severe infections may benefit from subcutaneous administration of recombinant human granulocyte-colony stimulating factor (rhG-CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\", section on 'Granulocyte-colony stimulating factor (G-CSF)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=see_link&amp;anchor=H4#H4\">",
"     \"Risk of infection in children with fever and non-chemotherapy-induced neutropenia\", section on 'Infection in patients with severe chronic neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only curative approach for patients with CD40L (or CD40) deficiency is allogeneic hematopoietic cell transplantation (HCT). In a series of 38 patients with CD40L deficiency treated by HCT from 1993 to 2002, overall survival was 68 percent, and disease-free survival was 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/62\">",
"     62",
"    </a>",
"    ]. The presence of lung disease and use of a mismatched unrelated donor were associated with poorer survival rate. The chance of survival was higher in patients without liver disease than in those with preexisting liver disease (72 versus 39 percent). A cumulative survival rate of &gt;70 percent was reported in 35 patients who received HCT in the period from 1995 to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/63\">",
"     63",
"    </a>",
"    ]. Similar survival rates were described in a smaller single-center study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactivation of",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    infection, even when subclinical, may occur after HCT and may lead to disseminated infection and death in patients with CD40L or CD40 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/65\">",
"     65",
"    </a>",
"    ]. For this reason, active surveillance against",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    infection should be performed periodically by polymerase chain reaction (PCR) on stool samples. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful immune reconstitution was reported in one CD40L-deficient patient with severe",
"    <span class=\"nowrap\">",
"     liver/biliary",
"    </span>",
"    tract disease after combined bone marrow and liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/66\">",
"     66",
"    </a>",
"    ]. However, other patients in similarly severe condition did not survive after the combined procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety and potential benefit of treatment with recombinant CD40L was explored in three CD40L-deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/46\">",
"     46",
"    </a>",
"    ]. Increased secretion of Th1 cytokines upon in vitro activation of mononuclear cells and in vivo acquisition of the capacity to mount delayed-type hypersensitivity were demonstrated, although the latter effect ceased after rhCD40L was discontinued. No variations in immunoglobulin levels and specific antibody responses were noted. Treatment with hrCD40L might be a valid treatment option for CD40L-deficient patients with biliary Cryptosporidium disease, in light of the lack of effective treatment for patients with active",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    infection and of improved T cell function following administration of hrCD40L [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18934075\">",
"    <span class=\"h2\">",
"     AID and UNG deficiencies and HIGM4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hyper-IgM syndrome due to AID or UNG deficiency is based upon immune globulin replacement therapy that can be administered intravenously or subcutaneously. This treatment results in marked reduction of the frequency and severity of infections, and may also reduce the occurrence of lymphoid hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/3,42\">",
"     3,42",
"    </a>",
"    ]. Patients with HIGM4 are also treated with immune globulin replacement therapy. Immune globulin therapy is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is recommended in patients who have developed chronic complications, such as bronchiectasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6150?source=see_link\">",
"     \"Management of bronchiectasis in children without cystic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of autoimmune manifestations in AID deficiency requires use of immunosuppressive regimens, as in other autoimmune disorders that are not associated with immunodeficiency. The treatment of these is discussed in topic reviews on the specific autoimmune disorder, eg, inflammatory bowel disease. (See appropriate topics.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462648\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death rates of 23 percent and 10 percent were reported in two series of patients with CD40L deficiency from Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"     31",
"    </a>",
"    ] and the United States (US) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/27\">",
"     27",
"    </a>",
"    ], respectively. This difference may reflect the higher frequency of severe biliary tract disease among European CD40L-deficient patients. The median survival of CD40L-deficient males who had not received hematopoietic cell transplantation (HCT) was less than 25 years in the European study. The oldest patient in the US series had died at 39 years of age before enrollment in the registry. However, poor survival in these series may also reflect inadequate knowledge and suboptimal treatment of the disease in several patients. Follow-up studies in cohorts of more recently diagnosed patients will be important to refine current prognosis of CD40L deficiency.",
"   </p>",
"   <p>",
"    Severe and opportunistic infections,",
"    <span class=\"nowrap\">",
"     liver/biliary",
"    </span>",
"    tract disease, and malignancies are the most important causes of death in CD40L deficiency. Monitoring of liver status by regular assessment of liver function and by ultrasound evaluation (at least once a year), and PCR-based testing for the presence of",
"    <em>",
"     Cryptosporidium",
"    </em>",
"    and",
"    <em>",
"     Microsporidium",
"    </em>",
"    in the stool, are important to detect early signs of infection. In patients who develop infection with one of these organisms, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    should be used to prevent progression of the infection, which may otherwise ultimately lead to severe biliary tract and liver complications. Similar considerations apply to patients with CD40 deficiency.",
"   </p>",
"   <p>",
"    The long-term prognosis of AID and UNG deficiency is less severe. In this disease, regular use of immune globulin replacement therapy and prompt treatment of infections are effective in avoiding development of chronic lung disease and early death.",
"   </p>",
"   <p>",
"    Spontaneous resolution by the age of approximately six years was reported in some patients with HIGM4 who did not have identifiable defects or deficiency in CD40L, CD40, NEMO, UNG, or AICDA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/32/21001/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients with this type of hyper-IgM should be reevaluated periodically to see if immune function has normalized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4462656\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hyperimmunoglobulin M (hyper-IgM or HIGM) syndromes include a heterogeneous group of congenital and acquired conditions characterized by defective class-switch recombination (CSR), resulting in normal or increased levels of serum IgM associated with deficiency of IgG, IgA, and IgE and poor antibody function. (See",
"      <a class=\"local\" href=\"#H4462576\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All genetically-determined forms of hyper-IgM syndrome are characterized by defective CSR (",
"      <a class=\"graphic graphic_table graphicRef86094 \" href=\"UTD.htm?2/52/2893\">",
"       table 1",
"      </a>",
"      ). Some forms also have impairment of somatic hypermutation (SHM), with production of low, rather than high, affinity antibodies. Impaired CSR in hyper-IgM syndrome is due to B cell-intrinsic abnormalities or to defects that involve several types of immune cells. This difference in the pathogenesis accounts for the distinctive clinical features in the various forms of hyper-IgM syndrome. (See",
"      <a class=\"local\" href=\"#H4462584\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CD40 ligand (CD40L) deficiency is the most common form of hyper-IgM syndrome. It is inherited as an X-linked trait. This disease affects the interaction between activated CD4",
"      <sup>",
"       +",
"      </sup>",
"      T cells and cell types expressing CD40 (B cells, dendritic cells,",
"      <span class=\"nowrap\">",
"       monocyte/macrophages,",
"      </span>",
"      platelets, activated endothelial and epithelial cells).",
"      <br/>",
"      <br/>",
"      The clinical phenotype of CD40L deficiency is marked not only by recurrent sinopulmonary infections, but also by opportunistic infections and liver disease.",
"      <br/>",
"      <br/>",
"      CD40 deficiency affects the interaction of the same cell types as CD40L deficiency and therefore has a similar clinical presentation. (See",
"      <a class=\"local\" href=\"#H4462584\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4462592\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4468219\">",
"       'In CD40L or CD40 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast, activation induced cytidine deaminase (AID) deficiency and uracil N-glycosylase (UNG) deficiency account for hyper-IgM syndrome due to B cell-intrinsic-defects of CSR.",
"      <br/>",
"      <br/>",
"      These patients suffer from recurrent sinopulmonary infections, enlargement of lymph nodes and tonsils, and are at higher risk for autoimmune manifestations. (See",
"      <a class=\"local\" href=\"#H4462584\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4462592\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4468226\">",
"       'In AID deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flow cytometry-based analysis of CD40L expression on the surface of in vitro activated CD4",
"      <sup>",
"       +",
"      </sup>",
"      lymphocytes can facilitate the diagnosis of X-linked hyper-IgM syndrome and can also be used for carrier detection. Ultimately, mutation analysis should be used for definitive confirmation of genetically-determined hyper-IgM syndrome. There is one form of hyper-IgM (HIGM4) for which molecular basis remains unknown. (See",
"      <a class=\"local\" href=\"#H4462624\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4462592\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of acquired forms of hyper-IgM include congenital rubella syndrome, antiepileptic drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ), and tumors (T cell leukemia and lymphomas). (See",
"      <a class=\"local\" href=\"#H25649353\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with hyper-IgM should be managed by an immunology specialist in addition to their primary care provider. Treatment of hyper-IgM syndrome requires regular administration of immune globulin. Additional measures are used in patients with CD40L and with CD40 deficiency. These include prevention of",
"      <em>",
"       Pneumocystis jirovecii",
"      </em>",
"      infection by means of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , hygienic measures to reduce the risk of",
"      <em>",
"       Cryptosporidium",
"      </em>",
"      infection (",
"      <a class=\"graphic graphic_table graphicRef86095 \" href=\"UTD.htm?12/14/12523\">",
"       table 2",
"      </a>",
"      ), and regular monitoring of liver function. However, the only definitive cure for CD40L (or CD40) deficiency is hematopoietic cell transplantation. (See",
"      <a class=\"local\" href=\"#H4462640\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/1\">",
"      Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 1992; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/2\">",
"      Kracker S, Gardes P, Mazerolles F, Durandy A. Immunoglobulin class switch recombination deficiencies. Clin Immunol 2010; 135:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/3\">",
"      Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. Br J Haematol 2010; 149:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/4\">",
"      Ameratunga R, Woon ST, Koopmans W, French J. Cellular and molecular characterisation of the hyper immunoglobulin M syndrome associated with congenital rubella infection. J Clin Immunol 2009; 29:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/5\">",
"      Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class switch recombination. Annu Rev Immunol 2008; 26:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/6\">",
"      Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/7\">",
"      Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000; 102:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/8\">",
"      Imai K, Slupphaug G, Lee WI, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 2003; 4:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/9\">",
"      P&eacute;ron S, Metin A, Gard&egrave;s P, et al. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 2008; 205:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/10\">",
"      Maul RW, Gearhart PJ. AID and somatic hypermutation. Adv Immunol 2010; 105:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/11\">",
"      Korth&auml;uer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/12\">",
"      Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993; 259:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/13\">",
"      Aruffo A, Farrington M, Hollenbaugh D, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993; 72:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/14\">",
"      DiSanto JP, Bonnefoy JY, Gauchat JF, et al. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993; 361:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/15\">",
"      Fuleihan R, Ramesh N, Loh R, et al. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A 1993; 90:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/16\">",
"      Ferrari S, Giliani S, Insalaco A, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A 2001; 98:12614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/17\">",
"      Meyers G, Ng YS, Bannock JM, et al. Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proc Natl Acad Sci U S A 2011; 108:11554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/18\">",
"      Jain A, Ma CA, Liu S, et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001; 2:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/19\">",
"      Hanson EP, Monaco-Shawver L, Solt LA, et al. Hypomorphic nuclear factor-kappaB essential modulator mutation database and reconstitution system identifies phenotypic and immunologic diversity. J Allergy Clin Immunol 2008; 122:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/20\">",
"      D&ouml;ffinger R, Smahi A, Bessia C, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001; 27:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/21\">",
"      Pan-Hammarstr&ouml;m Q, L&auml;hdesm&auml;ki A, Zhao Y, et al. Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation. J Exp Med 2006; 203:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/22\">",
"      de Saint Basile G, Tabone MD, Durandy A, et al. CD40 ligand expression deficiency in a female carrier of the X-linked hyper-IgM syndrome as a result of X chromosome lyonization. Eur J Immunol 1999; 29:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/23\">",
"      Imai K, Shimadzu M, Kubota T, et al. Female hyper IgM syndrome type 1 with a chromosomal translocation disrupting CD40LG. Biochim Biophys Acta 2006; 1762:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/24\">",
"      Kasahara Y, Kaneko H, Fukao T, et al. Hyper-IgM syndrome with putative dominant negative mutation in activation-induced cytidine deaminase. J Allergy Clin Immunol 2003; 112:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/25\">",
"      Imai K, Zhu Y, Revy P, et al. Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. Clin Immunol 2005; 115:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/26\">",
"      Imai K, Catalan N, Plebani A, et al. Hyper-IgM syndrome type 4 with a B lymphocyte-intrinsic selective deficiency in Ig class-switch recombination. J Clin Invest 2003; 112:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/27\">",
"      Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003; 82:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/28\">",
"      Kutukculer N, Moratto D, Aydinok Y, et al. Disseminated cryptosporidium infection in an infant with hyper-IgM syndrome caused by CD40 deficiency. J Pediatr 2003; 142:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/29\">",
"      Mazzolari E, Lanzi G, Forino C, et al. First report of successful stem cell transplantation in a child with CD40 deficiency. Bone Marrow Transplant 2007; 40:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/30\">",
"      Lanzi G, Ferrari S, Vihinen M, et al. Different molecular behavior of CD40 mutants causing hyper-IgM syndrome. Blood 2010; 116:5867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/31\">",
"      Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997; 131:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/32\">",
"      Aghamohammadi A, Parvaneh N, Rezaei N, et al. Clinical and laboratory findings in hyper-IgM syndrome with novel CD40L and AICDA mutations. J Clin Immunol 2009; 29:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/33\">",
"      Simon G, Simon G, Erd&ouml;s M, Mar&oacute;di L. Invasive Cryptococcus laurentii disease in a nine-year-old boy with X-linked hyper-immunoglobulin M syndrome. Pediatr Infect Dis J 2005; 24:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/34\">",
"      Yong PF, Post FA, Gilmour KC, et al. Cerebral toxoplasmosis in a middle-aged man as first presentation of primary immunodeficiency due to a hypomorphic mutation in the CD40 ligand gene. J Clin Pathol 2008; 61:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/35\">",
"      Suzuki H, Takahashi Y, Miyajima H. Progressive multifocal leukoencephalopathy complicating X-linked hyper-IgM syndrome in an adult. Intern Med 2006; 45:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/36\">",
"      Aschermann Z, Gomori E, Kovacs GG, et al. X-linked hyper-IgM syndrome associated with a rapid course of multifocal leukoencephalopathy. Arch Neurol 2007; 64:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/37\">",
"      Hayward AR, Levy J, Facchetti F, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/38\">",
"      Erdos M, Garami M, R&aacute;k&oacute;czi E, et al. Neuroendocrine carcinoma associated with X-linked hyper-immunoglobulin M syndrome: report of four cases and review of the literature. Clin Immunol 2008; 129:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/39\">",
"      Filipovich AH, Mathur A, Kamat D, et al. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency 1994; 5:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/40\">",
"      Lopez-Granados E, Temmerman ST, Wu L, et al. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc Natl Acad Sci U S A 2007; 104:5056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/41\">",
"      Minegishi Y, Lavoie A, Cunningham-Rundles C, et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol 2000; 97:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/42\">",
"      Quartier P, Bustamante J, Sanal O, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol 2004; 110:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/43\">",
"      Agematsu K, Nagumo H, Shinozaki K, et al. Absence of IgD-CD27(+) memory B cell population in X-linked hyper-IgM syndrome. J Clin Invest 1998; 102:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/44\">",
"      Puga I, Cols M, Cerutti A. Innate signals in mucosal immunoglobulin class switching. J Allergy Clin Immunol 2010; 126:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/45\">",
"      Lee WI, Torgerson TR, Schumacher MJ, et al. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood 2005; 105:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/46\">",
"      Jain A, Kovacs JA, Nelson DL, et al. Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand. Blood 2011; 118:3811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/47\">",
"      Jain A, Atkinson TP, Lipsky PE, et al. Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. J Clin Invest 1999; 103:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/48\">",
"      DeKruyff RH, Gieni RS, Umetsu DT. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. J Immunol 1997; 158:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/49\">",
"      Facchetti F, Appiani C, Salvi L, et al. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J Immunol 1995; 154:6624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/50\">",
"      Cabral-Marques O, Arslanian C, Ramos RN, et al. Dendritic cells from X-linked hyper-IgM patients present impaired responses to Candida albicans and Paracoccidioides brasiliensis. J Allergy Clin Immunol 2012; 129:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/51\">",
"      Fontana S, Moratto D, Mangal S, et al. Functional defects of dendritic cells in patients with CD40 deficiency. Blood 2003; 102:4099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/52\">",
"      Brugnoni D, Air&ograve; P, Graf D, et al. Ontogeny of CD40L [corrected] expression by activated peripheral blood lymphocytes in humans. Immunol Lett 1996; 49:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/53\">",
"      Gilmour KC, Walshe D, Heath S, et al. Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM. Mol Pathol 2003; 56:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/54\">",
"      Bonilla FA, Geha RS. CD154 deficiency and related syndromes. Immunol Allergy Clin North Am 2001; 21:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/55\">",
"      Seyama K, Nonoyama S, Gangsaas I, et al. Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome. Blood 1998; 92:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/56\">",
"      Notarangelo LD, Peitsch MC, Abrahamsen TG, et al. CD40lbase: a database of CD40L gene mutations causing X-linked hyper-IgM syndrome. Immunol Today 1996; 17:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/57\">",
"      Chou J, Hanna-Wakim R, Tirosh I, et al. A novel homozygous mutation in recombination activating gene 2 in 2 relatives with different clinical phenotypes: Omenn syndrome and hyper-IgM syndrome. J Allergy Clin Immunol 2012; 130:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/58\">",
"      Farrington M, Grosmaire LS, Nonoyama S, et al. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci U S A 1994; 91:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/59\">",
"      Brugnoni D, Air&ograve; P, Lebovitz M, et al. CD4+ cells from patients with Common Variable Immunodeficiency have a reduced ability of CD40 ligand membrane expression after in vitro stimulation. Pediatr Allergy Immunol 1996; 7:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/60\">",
"      O'Gorman MR, Zaas D, Paniagua M, et al. Development of a rapid whole blood flow cytometry procedure for the diagnosis of X-linked hyper-IgM syndrome patients and carriers. Clin Immunol Immunopathol 1997; 85:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/61\">",
"      Wang WC, Cordoba J, Infante AJ, Conley ME. Successful treatment of neutropenia in the hyper-immunoglobulin M syndrome with granulocyte colony-stimulating factor. Am J Pediatr Hematol Oncol 1994; 16:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/62\">",
"      Gennery AR, Khawaja K, Veys P, et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 2004; 103:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/63\">",
"      Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/64\">",
"      Tomizawa D, Imai K, Ito S, et al. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol 2004; 76:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/65\">",
"      McLauchlin J, Amar CF, Pedraza-D&iacute;az S, et al. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003; 22:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/66\">",
"      Hadzi�� N, Pagliuca A, Rela M, et al. Correction of the hyper-IgM syndrome after liver and bone marrow transplantation. N Engl J Med 2000; 342:320.",
"     </a>",
"    </li>",
"    <li>",
"     Notarangelo L, Harvard Medical School, 2012, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/32/21001/abstract/68\">",
"      Karaca NE, Durandy A, Gulez N, et al. Study of patients with Hyper-IgM type IV phenotype who recovered spontaneously during late childhood and review of the literature. Eur J Pediatr 2011; 170:1039.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13567 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-956556EC73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21001=[""].join("\n");
var outline_f20_32_21001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4462656\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462576\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462584\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462592\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462600\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462608\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4468219\">",
"      In CD40L or CD40 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4468226\">",
"      In AID deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18933964\">",
"      In other types of hyper-IgM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462616\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462624\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18934025\">",
"      Of CD40L deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18934039\">",
"      Of CD40 deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18934046\">",
"      Of AID or UNG deficiency or HIGM4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25649353\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H327122727\">",
"      Ataxia-telangiectasia (AT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H327122757\">",
"      Nijmegen breakage syndrome (NBS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H327122742\">",
"      Common variable immunodeficiency (CVID)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H327122772\">",
"      Congenital rubella syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462632\">",
"      CARRIER DETECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462640\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18934067\">",
"      CD40L and CD40 deficiencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18934075\">",
"      AID and UNG deficiencies and HIGM4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462648\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4462656\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/13567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/13567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2893\" title=\"table 1\">",
"      Features of genetically-determined hyper-IgM syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/14/12523\" title=\"table 2\">",
"      Cryptosporidium infection prevention in CD40L deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/28/17866?source=related_link\">",
"      Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/58/40873?source=related_link\">",
"      Combined immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38617?source=related_link\">",
"      Common variable immunodeficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10010?source=related_link\">",
"      Congenital rubella syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/6/23656?source=related_link\">",
"      Flow cytometry for the diagnosis of primary immunodeficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/0/6150?source=related_link\">",
"      Management of bronchiectasis in children without cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/439?source=related_link\">",
"      Nijmegen breakage syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30022?source=related_link\">",
"      Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_32_21002="Barretts esoph goblet cells";
var content_f20_32_21002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80518%7EGAST%2F68357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80518%7EGAST%2F68357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 273px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy specimen of a patient with Barrett's esophagus shows intestinalized columnar epithelium with goblet cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a biopsy specimen from a patient with Barrett's esophagus has been stained with Alcian blue, which demonstrates the abundant goblet cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21002=[""].join("\n");
var outline_f20_32_21002=null;
var title_f20_32_21003="Dynamic parameters for intraoperative fluid therapy";
var content_f20_32_21003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dynamic parameters for intraoperative fluid therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systolic pressure variations",
"       </td>",
"       <td>",
"        Easy to manually calculate",
"       </td>",
"       <td>",
"        Depends on diastolic pressure and on changes in pleural pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pulse pressure variations",
"       </td>",
"       <td rowspan=\"2\">",
"        Directly related to stroke volume variations",
"       </td>",
"       <td>",
"        Not easy to manually calculate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need specific device for continuous display",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke volume variations",
"       </td>",
"       <td>",
"        Accurate analysis despite multiple extrasystoles",
"       </td>",
"       <td>",
"        Need specific device",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Biais M, Ouattara A, Janvier G, Sztark F. Case scenario: Respiratory variations in arterial pressure for guiding fluid management in mechanically ventilated patients. Anesthesiology 2012; 116:1354. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21003=[""].join("\n");
var outline_f20_32_21003=null;
var title_f20_32_21004="Whole milk diets";
var content_f20_32_21004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Whole milk diets for use during the rehabilitation phase of treatment for malnutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           To make the starter diet from milk:",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Mix 50 g sugar and 10 mL vegetable oil together thoroughly.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Add 150 mL boiled whole (full cream) milk and 10 mL of the electrolyte solution (see paragraph 3) if used.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Make up to 500 mL with boiled water. Whisk to stop oil separating out or mix vigorously before serving. This feed keeps up to 12 hours. Make more when necessary.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           In the evening make sure there is enough for the night feeds.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Feed at a rate of 130 mL/kg body weight/24 hours. Divide into eight feeds and feed every three hours.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           A child who is breastfed should be encouraged to suckle after drinking the milk feed.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           <strong>",
"            Never add salt,",
"           </strong>",
"           explain to the parent that the child needs sweet not salty food.",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tr>",
"          <td class=\"subtitle1_single\">",
"           To make a high energy high nutrient rehabilitation diet from milk:",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Mix 40 g sugar and 10 mL vegetable oil.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Add 440 mL boiled whole milk and 10 mL of the electrolyte solution.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           Make up to 500 mL with boiled water and whisk vigorously.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           For two days, feed at same frequency and amount as the initial diet, then increase the amount by 10 mL/feed and reduce frequency of feeds to every four hours. Feed at a rate of approximately 200 mL/kg body weight/day (or more if child wants it). When given four hourly, each feed should be 166 mL.",
"          </td>",
"         </tr>",
"         <tr>",
"          <td>",
"           If milk is difficult to get, make a thick cereal porridge and add oil or margarine or sugar and bean, pea or peanut flour, peanut butter or eggs. Start giving fruits and vegetables, particularly those rich in vitamin A.",
"          </td>",
"         </tr>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Improving child nutrition: Treating severe malnutrition. Child Health Dialogue 200; 19. Copyright &copy;2000 Healthlink.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21004=[""].join("\n");
var outline_f20_32_21004=null;
var title_f20_32_21005="DDx blister pustule infant";
var content_f20_32_21005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Vesiculopustular lesions in neonates and infants that require treatment and/or monitoring",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Condition",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Significance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Infectious conditions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Congenital herpes simplex virus (HSV)",
"      </td>",
"      <td>",
"       Grouped or single vesicles on erythematous base in crops on skin and mucous membranes; lesions usually appear between one and two weeks of age; may be associated with nonspecific signs of serious illness: temperature instability, respiratory distress, poor feeding, lethargy",
"      </td>",
"      <td>",
"       Requires antiviral therapy; significant morbidity and mortality if untreated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neonatal varicella zoster virus",
"      </td>",
"      <td>",
"       Grouped or single vesicles on erythematous base in crops on skin and mucous membranes",
"      </td>",
"      <td>",
"       Requires antiviral therapy; associated with significant morbidity and mortality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Congenital syphilis",
"      </td>",
"      <td>",
"       Blisters, erosions that frequently involve the palms and soles; other manifestations include rhinitis, anemia, jaundice, hepatomegaly",
"      </td>",
"      <td>",
"       Requires antibiotic therapy; late manifestations in untreated infants may include central nervous system, skeletal, and dental abnormalities; hearing loss; and interstitial keratitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Staphylococcal pustulosis",
"      </td>",
"      <td>",
"       Erythematous papules, pustules, honey-colored crusts often in areas of trauma",
"      </td>",
"      <td>",
"       Requires antibiotic therapy; gram stain and culture of lesions should be obtained; may be associated with systemic/invasive infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Staphylococcal scalded skin syndrome (SSSS)",
"      </td>",
"      <td>",
"       Fever, irritability, diffuse blanching erythema, flaccid blisters; positive Nikolsky sign*",
"      </td>",
"      <td>",
"       Requires antibiotic therapy; cultures should be obtained from any suspected focus of infection (eg, blood, urine, nasopharynx, umbilicus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Streptococcal infections",
"      </td>",
"      <td>",
"       May mimic Staphylococcal infections",
"      </td>",
"      <td>",
"       Same as for Staphylococcal pustulosis and SSSS",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Listeria",
"      </td>",
"      <td>",
"       Pustules of the skin and mucus membranes may be present in early onset disease (&lt;7 days of age)",
"      </td>",
"      <td>",
"       Requires antibiotic therapy; may be associated with septicemia and/or meningitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Candidiasis",
"      </td>",
"      <td>",
"       Erythematous macules and papules evolving to pustules and vesicles",
"      </td>",
"      <td>",
"       Requires antifungal therapy; has the potential to disseminate via the bloodstream in susceptible hosts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Congenital disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Epidermolysis bullosa",
"      </td>",
"      <td>",
"       Blister development with little or no trauma",
"      </td>",
"      <td>",
"       Management involves prevention of trauma, careful wound care, and treatment of infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Epidermolytic hyperkeratosis",
"      </td>",
"      <td>",
"       Widespread blistering and erythema and or hyperkeratosis; denuded areas of skin",
"      </td>",
"      <td>",
"       Increased susceptibility to cutaneous infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Aplasia cutis congenita",
"      </td>",
"      <td>",
"       Erosions present at birth that reepitheliaze to form hypertrophic or atrophic scar; involves the epidermis and dermis",
"      </td>",
"      <td>",
"       May be associated with other disorders (eg, trisomy 13, 4p-)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Incontinentia pigmenti",
"      </td>",
"      <td>",
"       Four stages that may occur simultaneously: linear streaks of erythematous papules and vesicles; warty papules or plaques in linear or swirling patterns; swirled; hypopigmented patches or streaks",
"      </td>",
"      <td>",
"       Majority of cases associated with neurologic, ocular, dental, and structural abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Miscellaneous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Scabies",
"      </td>",
"      <td>",
"       May be seen in infants as young as 3 to 4 weeks of age, but never present at birth; vesicles, pustules, and papules, rare burrows on hands, feet, trunk, genitalia",
"      </td>",
"      <td>",
"       Requires treatment with scabicide and measures to prevent spread",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cutaneous mastocytosis",
"      </td>",
"      <td>",
"       Bullous eruptions with hemorrhage; positive Darier sign&bull;",
"      </td>",
"      <td>",
"       Requires symptomatic therapy and avoidance of triggers",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Nikolsky sign: separation of the upper dermis and wrinkling of the skin with application of gentle pressure.",
"     <br>",
"      &bull; Darier sign: urticaria and erythema with rubbing, scratching, or stroking.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21005=[""].join("\n");
var outline_f20_32_21005=null;
var title_f20_32_21006="Traumatic neck stiffness in children";
var content_f20_32_21006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61811&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Neck stiffness or torticollis following trauma in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     C-spine: cervical spine.",
"     <br/>",
"     * May coexist with a spinal fracture, subluxation or ligamentous injury.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21006=[""].join("\n");
var outline_f20_32_21006=null;
var title_f20_32_21007="Gram stain abscess 11A answer";
var content_f20_32_21007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinomyces",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of aspirate from oral abscess (x1000) shows abundant inflammatory cells and thin Gram positive, branching filaments consistent with either Actinomyces or Nocardia; the latter stains red on modified acid-fast stain, while the former does not. Actinomyces is frequently isolated from abscesses related to the oral cavity. A. israeli grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_32_21007=[""].join("\n");
var outline_f20_32_21007=null;
